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THE PREFRONTAL CORTEX 
 
The expanded cognitive abilities of man have been attributed to the fact that the 
frontal cortex of humans is enlarged relative to lower primates and mammals. For 
example, Brodmann (1912) argued that the human frontal cortex is 6% larger than the 
chimpanzee’s, based on “total frontal lobe surface”. However, subsequent studies 
emphasized that the frontal cortex in human brains is not larger, relative to the rest of 
the brain, when compared to a number of closely related great apes, including the 
chimapanzee (Semendeferi et al., 2001; Bush and Allman, 2004). Understanding the 
frontal cortex and its functions has been of significant interest for over a hundred years. 
However, due to moral (and legal) complications, significant manipulations in man are 
not often pursued, making the definition of a homologous region in a model organism 
critical to the study of the frontal cortex. 
The frontal cortex can be separated into a number of different areas with distinct 
cytoarchitectonics, including what has been termed the prefrontal cortex (PFC). The 
prefrontal cortex can be subdivided into even smaller regions. Significant differences 
have been reported in the relative volume of these subdivisions, specifically Brodmann’s 
areas 10. Brodmann’s area 10 is the most anterior portion of the frontal cortex, and is 
significantly enlarged in humans (1.2% of total brain volume) relative to great apes and 
other primates (0.46-0.74%; (Fuster, 2001; Semendeferi et al., 2001). Lesions of this 
region have been associated with an impairment of future planning (Fuster, 2001), thus 
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increased volume of this region suggests that humans may have an enhanced ability to 
perform higher-order cognitive tasks.  
 Absolute size of the brain, including the frontal cortex, is much enlarged in 
primates, relative to rodents such as the rat and mouse. Differences in relative size also 
exist in the prefrontal cortex of humans and non-human primates when compared to 
lower organisms. Because of the functional attributes of the prefrontal cortex as seen in 
primates, and the limited ability to study these attributes in humans and great apes in 
detail, considerable attention has been devoted to establishing that non-primate 
species, particularly rats and mice, have a prefrontal cortex (see Uylings et al., 2003).  
 
Defining the Prefrontal Cortex  
 
Cytoarchitectonics. Homologous regions of the brain across different species are 
arguably best defined based on three criteria: cytoarchitecture, connectivity, and 
function. In 1870, Gustav Fritsch and Eduard Hitzig published “On the Electrical 
Excitability of the Cerebrum,” which established that “a part of the convexity of the 
hemisphere of the brain of the dog is motor…another part is not motor. The motor part, 
in general, is more in front, the non-motor part more behind. By electrical stimulation of 
the motor part, one obtains combined muscular contractions of the opposite side of the 
body” (Fritsch and Hitzig, republished 2009). Furthermore, these mapping studies 
demonstrated that there was another area rostral to the motor cortex that was 
“electrically inexcitable” (Fritsch and Hitzig, republished 2009), meaning that stimulation 
of this area, did not result in peripheral muscle contractions. These studies were 
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followed by cytoarchitectonic analyses, which noted that the previously described 
inexcitable area could also be distinguished from the premotor cortex by the existence 
of a granular layer IV, located rostral to the agranular premotor regions (Kolb, 1984; 
Uylings et al., 2003). However, the granular layer IV rostral to the premotor area of the 
frontal cortex, as described by Brodmann and others, was found to be extremely thin or 
even non-existent in lower mammals, suggesting that, by this definition, the prefrontal 
cortex is limited to primates, and is not present in lower order mammals (Preuss, 1995). 
Thus, in rodents there are 5 layers, including a cell-sparse layer I, layers II and III (which 
collectively provide most of the efferent projections to other cortices), a wide layer V 
with deep and superficial sublamina (the major source of subcortical projections), and a 
layer V of multiple cell types that gives rise to thalamic projections. 
 
Connectivity. Cytoarchitectonic findings led to further efforts to define a brain region in 
lower animal species that resembled the primate PFC through connectivity studies. 
Rose and Woolsey demonstrated that the thalamic nuclei project to distinct regions of 
the cortex (Rose and Woolsey, 1949). Building from the work of Rose and Woolsey, 
Akert suggested that homologs of the prefrontal cortex could be defined by the medial 
dorsal thalamic (MD) input, which sends a massive projection to the primate and rodent 
frontal cortices (Akert and Monakow, 1980; Semendeferi et al., 2002; Bush and Allman, 
2004). In addition to the MD projection to the frontal cortex, there is a dopamine 
innervation of the frontal cortex derived from the midbrain ventral tegmental area (VTA; 
Divac et al., 1978a; Slopsema et al., 1982; Fuster, 2001; Semendeferi et al., 2001) that 
overlaps with the MD input.  Similarly, there is a projection of the basolateral amygdala 
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(BLA) onto the frontal cortex that overlaps in part with that of the MD input (Gerfen and 
Clavier, 1979; Fuster, 2001).  These anatomical studies, together with functional data, 
led Divac to suggest that it is not the input from any one area, but a zone of overlap of 
distinct afferents which defines the PFC. Specifically, Divac argued for the overlap of 
the MD, VTA, and BLA inputs in defining the frontal region designated the PFC in 
rodents, cats, opossum, tree shrews, and pigeons (Björklund et al., 1978; Lindvall et al., 
1978; Markowitsch et al., 1978; Divac et al., 1978a; 1978b; 1985; Uylings et al., 2003). 
Specifically, in the rat this overlap occurs in the prelimbic cortex (area 32), as well as in 
a region dorsal to the rhinal sulcus.  
 
Functional studies. Disruption of the prefrontal cortex in both humans and non-human 
primates leads to significant changes in working memory, response inhibition, and other 
cognitive functions (Brutkowski, 1965; Jacobs et al., 2007; Fritsch and Hitzig, 2009). A 
famous example of the functional effects of frontal lobe damage is the case of Phineas 
Gage. Gage, working on construction crew laying railroad tracks in the mid-19th century, 
suffered an accident in which a large metal rod was driven through his left frontal lobe. 
He survived for 12 years. After his accident, friends and family members described 
significant personality changes, including speaking “grossest profanity”, displaying “little 
deference for his fellows” and an inability to stick with plans. These changes have since 
been attributed to the loss of frontal lobe function. Over a hundred years after his death, 
Gage’s case continues to garner significant interest. (Ratiu et al., 2004). Two recent 
studies used in vivo imaging techniques, including x-ray, CAT scan, and 3-D modeling, 
to reconstruct the exact trajectory of the rod that passed through Gage’s brain and to 
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determine what frontal cortical regions were affected (Ratiu et al., 2004; Damasio et al., 
1994).  These studies both concluded that there was dorsolateral prefrontal cortex 
damage, although one study suggested that the damage was confined to one 
hemisphere (Ratiu et al., 2004), while the other concluded that there was some degree 
of bilateral damage (Damasio et al., 1994). The case of Phineas Gage and subsequent 
experimental studies (Jacobsen and Nissen, 1937; Leonard, 1969; Van Haaren et al., 
1985; Preuss, 1995; Joel et al., 1997) have concluded that the frontal cortex, and more 
specifically the medial prefrontal cortex (not the orbitofrontal cortex), is critically involved 
in executive function, attention, response inhibition, and working memory. 
In 1936, Jacobsen and Nissen described deficits in a delayed-response task 
following lesions of the frontal association areas in monkeys, over delay periods of 10 to 
100 seconds between the stimulus presentation and the monkey’s responses. The 
authors suggested that these changes could be attributed to working memory deficits. 
Studies in rats and other mammals subsequently described similar working memory 
deficits after lesions of prelimibic cortex, suggesting that subdivisions of the prefrontal 
cortex in lower animals, including rats, are functionally homologous to the regions of the 
primate prefrontal cortex (Rose and Woolsey, 1949; Brutkowski, 1965; Van Haaren et 
al., 1985; Joel et al., 1997).  
Performance of the Wisconsin Card Sorting Task (WCST) is a working memory 
test that is commonly used in neuropsychological assessments of humans.  Deficits in 
performance on the WCST, particularly perseverative errors, are seen in humans with 
PFC damage (Nelson, 1976; Nyhus and Barceló, 2009).  Similarly, non-human primates 
sustaining lesions of the PFC, mediodorsal thalamus, or the dopaminergic input to the 
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frontal cortex arising from the VTA, exhibit performance deficits in tasks analogous to 
the WCST (Brozoski et al., 1979; Sawaguchi and Goldman-Rakic, 1994; Joel et al., 
1997; Birrell and Brown, 2000; Mitchell and Dalrymple-Alford, 2005). This last sentence 
sounds like the monkeys had triple lesions.   
It can be argued that the prelimbic and infralimbic cortices of the medial wall of 
the rodent frontal (pregenual) cortex are homologous to, but not isomorphic with the 
primate dorsolateral PFC. Despite lacking a clearly-identifiable Layer IV, the rat medial 
PFC shares with its primate counterparts key connections with the MD, BLA, and VTA, 
and shares with the primate PFC roles in working memory and response inhibition. I do 
not include area 24b, or the region dorsal and lateral to area 24b, as the PFC; these 
regions appear to correspond to the primate anterior cingulate cortex and regions that, 
in the primate, spatially segregate as the frontal eye field, premotor, and supplementary 
motor cortex. I will use the term PFC to refer to the medial aspects of the rodent 
prelimbic and dorsal infralimbic cortices, as substantial and compelling evidence now 
exists that rats have prefrontal cortical areas (Kolb, 1984; Brown and Bowman, 2002; 




Cells of the Prefrontal Cortex 
 
Neurons have dominated neuroscience research as a whole, and PFC research has 
been no different. However, the brain is composed of a number of different cell types, 
including both neurons and glia.   
 
Neurons. Broadly, neurons in the PFC can be divided into pyramidal cells and 
interneurons. As indicated by their name, pyramidal cells have a distinct pyramidal-
shaped soma. Typical pyramidal cells consist of a large apical dendrite, which 
undergoes extensive branching in Layer I to form the apical tuft. Basal dendrites extend 
from the soma laterally and into deeper cortical layers (DeFelipe and Fariñas, 1992; 
Elston, 2003). Dendrites of pyramidal cells are studded with small protrusions known as 
dendritic spines, which are sites of glutamatergic input. Pyramidal cell axons typically 
enter the white matter of the forceps or corpus callosum, and project to and terminate in 
more distant subcortical or cortical targets, including but not limited to the MD, ventral 
tegmental area, amygdala, and contralateral PFC (Sesack et al., 1989; Carr and 
Sesack, 2000). In contrast, the axons of interneurons remain local; interneurons exhibit 
a wide variety of morphologies.  
 Pyramidal cells use glutamate as their neurotransmitter and make up roughly 70-
80% of neurons within the prefrontal cortex (deFelipe and Farinas, 1992). We are only 
beginning to appreciate the heterogeneity of pyramidal cells. These neurons differ 
substantially in soma size, dendritic arbor, and projection target, as well as exhibiting 
clear molecular differences (DeFelipe and Fariñas, 1992; Molyneaux et al., 2007).  
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Interneurons have a paucity of dendritic spines and use γ-aminobutyric acid 
(GABA) as their transmitter.  These local circuit neurons can be further subdivided on 
the basis of morphology, calcium-binding protein expression, and different neuropeptide 
co-transmitters. Early researchers defined numerous subtypes based on morphology 
and laminar distribution (for review see DeFelipe, 2002). Outside of morphological 
definitions, these cells are often classified by their differential, non-overlapping 
expression of three EF-hand calcium-binding proteins: calbindin, parvalbumin, and 
calretinin. However, these proteins are not expressed exclusively by any one 
morphologically-distinct type of interneuron. Similarly, the peptide transmitters, 
somatostatin (SOM), vasoactive intestinal peptide (VIP), cholecystokinin (CCK), and 
neuropeptide Y (NPY) are often used as markers of interneurons but are not exclusive 
to a distinct morphologically defined subtype. Interneurons have also been classified by 
their physiological properties, including fast-spiking, low-threshold-spiking, burst-spiking, 
irregular-spiking, and late-spiking subtypes. Once again, these physiological 
characteristics do not appear to correspond to any singular morphology, calcium-
binding protein expression, or peptide transmitter. All of these different characteristics 
can be used to define a large number of distinct types of interneurons. 
 
Glia. While neurons have consistently received the most interest from researchers and 
the general population, there is a growing interest in the role that glial cells play in the 
brain. The name glia literally means glue, suggesting that these cell types are the “glue” 
of the brain. Like neurons, glial cells have heterogeneous morphologies and functions. 
There are three major types of glia: microglia, oligodendrocytes, and astrocytes.  
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Microglia can be divided into a number of subtypes , including amoeboid, 
activated, ramified, phagocytotic, and others (Harry and Kraft, 2012). Microglia are 
primarily involved in the inflammatory response of the central nervous system (CNS), 
and have received significant attention in a variety of neurological and psychiatric 
conditions (for reviews see Frick et al., 2013; Tsuda et al., 2013).  
Oligodendrocytes form the myelin sheath that surrounds certain axons (Simons 
and Lyonns, 2013). Although subtypes of oligodendrocytes have been suggested (Butt 
et al., 1998), this idea has not received wide acceptance (Richardson et al., 2006). Loss 
or damage to oligodendrocytes has been implicated in diseases such as multiple 
sclerosis (see Compston and Coles, 2008).  
Astrocytes have been classically considered to be critically involved in ion 
homeostasis and blood-brain barrier function, and to play a support role for neurons. 
The name astrocyte suggests the star-like morphology that these cells exhibit, 
particularly in the human brain. Astrocytes have long been separated into fibrous and 
protoplasmic astrocytes, but are very diverse morphologically. The structural 
heterogeneity of these cells is only recently starting to be explored (Matyash and 
Kettenmann, 2010; Oberheim et al., 2012).  
Because the prefrontal cortex and astrocytes continue to garner significant 
attention, understanding the role that astrocytes play in the prefrontal cortex is of 
particular importance. Understanding astrocytic involvement in neuronal and 
intracellular signaling may shed light on dysfunction of the prefrontal cortex that occurs 









Astrocytes were first identified by Camillo Golgi in 1873, and were later given their name 
by Michael von Lenhossek in 1891 based on their star-shaped morphology 
(Kettenmann and Verkhratsky, 2008). Shortly thereafter, based on their location and 
morphology, astrocytes were categorized as protoplasmic or fibrous astrocytes, residing 
in the grey and white matter respectively (Andriezen, 1893). During the initial period of 
interest following the discovery of astrocytes, several prominent neuroscientists, 
including Golgi and Santiago Ramon y Cajal, suggested potential roles for astrocytes. 
Hypotheses ranged from metabolic support for neurons to direct regulation of synaptic 
connectivity (Verkhratsky et al., 2011). Unfortunately, due to technical limitations, these 
hypotheses remained uninvestigated for nearly 100 years, and astrocytes continued to 
be known only as the “glue” holding neurons together.  In the late 20th century, 
investigations began to evaluate the specific functional attributes of astrocytes, including 
metabolic and neurotrophic support, neurotransmitter uptake, neurotransmitter release, 
and even synapse formation. 
 
Astrocytes and Glutamate 
 
Astrocytes are critical in maintaining the levels of a number of extracellular molecules, 
such as K+, within homeostatic levels (Walz et al., 1984). Similarly, aquaporin proteins 
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localized to astrocytic membranes play an important role in regulating osmolality 
(Nagelhus et al., 1998; Manley et al., 2000). These studies began to shift the perception 
of astrocytes from “glue” holding neurons together, to playing an active role in 
intercellular communication.   
Astrocytes are also critically involved in the metabolism of glutamate, from 
release to inactivation of signaling. Glutamine synthetase, the enzyme responsible for 
the synthesis of the glutamate precursor glutamine, is expressed only in astrocytes 
(Erecińska and Silver, 1990). Glutamate, once released from axon terminals, is not 
enzymatically inactivated in the extracellular space. Instead, the termination of 
glutamate signaling occurs only through diffusion or uptake of the transmitter (Niciu et 
al., 2012). Astrocytes are the major cellular elements that accumulate glutamate from 
the extracellular space, and are responsible for >90% glutamate uptake in the adult 
cortex (Rothstein et al., 1996; Tanaka et al., 1997).  
 
Glutamate Uptake. High concentrations of glutamate are excitotoxic (Mehta et al., 
2013). Accordingly, considerable attention has been devoted to understanding the 
mechanisms involved in maintenance of extracellular glutamate levels. Excitatory amino 
acid transporters (EAATs) are the primary means of glutamate uptake and the resultant 
termination of glutamate signaling in the brain. This group of transporters has five 
members, designated EAAT 1-5 in humans (Grewer et al., 2014). In rodents, EAAT 1-3 
correspond to GLAST, GLT-1, and EAAC1, respectively, while EAAT4 and EAAT5 
share their nomenclature with their human homologues (Bridges and Esslinger, 2005). 







Human Nomenclature Rodent Nomenclature Localization 
EAAT1 GLAST Primarily astrocytes, some 
neurons 
EAAT2 GLT-1 Astrocytes 
EAAT3 EAAC1 Neurons 
EAAT4 EAAT4 Cerebellum 
EAAT5 EAAT5 Retina 
 
 
 Table 1. Nomenclature and cellular localization of the excitatory amino acid 
transporters (EAATs). GLAST, GLT-1 and EAAC1 (Bold) are those transporters 












Figure 1. Illustration of a synapse with presynaptic (glutamate), postsynaptic (pyramidal 
cell) and astrocytic elements, displaying the current understanding of the cellular 
localizations of the three glutamate transporters expressed in the prefrontal cortex. 
GLT-1 expression in the PFC is considered to be exclusive to astrocytes in the normal 
adult rat. Expression of EAAC1 as determined by ultrastructural studies appears to be 
present on neuronal cell bodies as well as dendrites, with an absence of axonal 
expression (Rothstein et al., 1994). GLAST is primarily expressed by astrocytes, 





Of the five EAAT proteins, GLAST, GLT-1, and EAAC1 are expressed in the cerebral 
cortex, but have different cellular distributions (Table 1, Figure 1). GLAST and GLT-1 
are localized primarily to astrocytes, while EAAC1 is localized to neurons. EAAT4 is 
localized to neurons of the cerebellum while EAAT5 is expressed exclusively in the 
retina (for reviews see Danbolt, 2001; Bridges and Esslinger, 2005; Kanai et al., 2013; 
Grewer et al., 2014).  
Examining the functional consequences of manipulating levels of these 
transporters has demonstrated their importance in preventing excitotoxity (Meldrum et 
al., 1999). For example, Rothstein and colleagues chronically treated spinal cord 
cultures with antisense oligonucleotides, effectively knocking out GLAST or GLT-1. This 
resulted in increased excitotoxicity with antisense GLT-1 leading to 32-fold increases in 
extracellular glutamate (Rothstein et al., 1996). Null mutant GLT-1 mice exhibit seizures 
early in life, with 50% of animals dying by 6 weeks, further demonstrating the 
physiological importance of glutamate transporters, particularly GLT-1 (Tanaka et al., 
1997). Tanaka et al. also reported that GLT-1 is responsible for >90% of glutamate 
uptake in the cortex (1997). These studies demonstrate a critical role for this family of 
transporters, particularly those localized to astrocytes, in the uptake of glutamate and 
termination of glutamate signaling. 
 
Glutamate Release. Although it has been known for the past 35 years that astrocytes 
are critically involved in glutamate uptake (Hertz et al., 1980; Walz et al., 1984), more 
recent studies indicate that astrocytes also release transmitters, including glutamate (for 
review see Hamilton and Attwell, 2010). In 1990, Cornell-Bell et al. were the first to 
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report that glutamate induces a rise in intracellular calcium levels in astrocytes, and that 
these increases can be propagated across astrocytes (Science). Furthermore, 
increasing calcium levels in astrocytes, as induced by glutamate, appears to lead to 
calcium influx by neighboring neurons and astrocytes (Cornell-Bell et al., 1990; Parri et 
al., 2001; Perea and Araque, 2005). Finally, a glutamate-induced increase in 
intracellular astrocyte calcium levels evokes the release of glutamate and other 
molecules (such as ATP and D-serine) from astrocytes into the extracellular space 
(Guthrie et al., 1999; Mothet et al., 2005; Hamilton et al., 2008). These data indicate that 
astrocytes release glutamate and other neurotransmitters, a process that has been 
termed gliotransmission (Bezzi and Volterra, 2001). 
Gliotransmission, in particular a process resembling neuronal vesicular release of 
neurotransmitters, remains controversial. A number of studies have shown that synaptic 
machinery necessary for vesicle fusion is present in the astrocyte, including 
synaptobrevin 2, syntaxins 1, 2 and 4, and also SAP23 (for review see Montana et al., 
2006). However this machinery is also required for endosomal fusion (Proux-
Gillardeaux et al., 2005; Oishi et al., 2006). Similarly, cultured astrocytes express a 
number of voltage gated-calcium channels including N-, L-, R-, and T-type channels 
(Latour et al., 2003), some of which are critical for neurotransmission. While much of the 
machinery exists for vesicular release of glutamate, one basic point has left some 
investigators skeptical: vesicles comparable to those found in neurons have not been 
described. Electron microscopy studies have reported the existence of vesicle-like 
structures in astrocytes that contain vesicular proteins such as the vesicular glutamate 
transporters 1 and 2 (Bezzi et al., 2004). However, these astrocytic “vesicles” are not 
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organized in the densely-packed and organized manner that is present in axon 
terminals, and they vary in size from 30 to 300nm compared to approximately 40 nm in 
neurons (Bezzi et al., 2004). While these factors suggest that the vesiscular-like 
organelles in axons may differ from those seen in astrocytes, single fusion events of 
these vesicle-like compartments to the plasma membrane of astrocytes can be 
visualized using total internal reflection fluorescence (TIRF) microscopy (Bowser and 
Khakh, 2007). For a review of gliotransmission refer to Parpura and Zorec (2010), which 
discusses exocytotic (vesicular-like) release of glutamate, ATP, peptides, and other 
signaling molecules from astrocytes. 
While vesicular release of gliotransmitters from astrocytes has been somewhat 
controversial other, less contested, mechanisms exist for astrocytic release of glutamate 
into the extracellular space, including channels, reversal of amino acid transporters, and 
antiporters. The antiporter system xC-, expressed by astrocytes, is a heterodimer 
comprised of both a light chain (xCT) and a heavy chain (4F2hc), and exchanges 
glutamate from the astrocyte to the extracellular space in exchange for a cystine 
molecule with a 1:1 stoichiometry (Niciu et al., 2012). Substrate specificity of system xC- 
is determined by xCT while 4F2hc is necessary for trafficking of xCT to the membrane 
(Sato et al., 2000; Wang et al., 2003; Sato et al., 2005).  The cystine brought into the 
cell is used in the synthesis of glutathione.  Astrocytes, by virtue of their role in 
glutathione production, have neuroprotective effects under certain conditions. For 
example, the cytotoxic effects of nitric oxide or glutamate exposure of primary cortical 
cultures are attenuated in the presence of a dialysate probe coated in astrocytes (Chen 
et al., 2001), while NMDA-induced excitotoxicity remains unaffected. Because of the 
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importance of cystine for glutathione production, many studies of xC- have focused on 
the influx of cystine and the production of glutathione rather than the consequences of 
glutamate efflux into the extracellular space (Shih et al., 2006). 
It has been difficult to untangle the relative contributions of astrocytes and 
neurons to extracellular glutamate levels in vivo. As new methods emerge, it will be 
important to determine to what degree, and under which physiological or 
pathophysiological conditions, astrocytic release of glutamate is functionally significant 
in vivo. However, the body of work that was sparked by the suggestion of glutamate 
release from astrocytes has turned attention from the homeostatic role of astrocytes to 
their active role in signaling in the brain. 
 
Astrocyte Expression of Neurotransmitter Receptors 
 
Neurotransmitter receptors have mainly been studied from the vantage point of 
neurons. The hypothesis that glia participate in synaptic signaling has been 
strengthened by the fact that many transmitter receptors are expressed by astrocytes.  
 
Dopamine Receptors. Autoradiographic studies using tritiated dopamine binding 
suggested the presence of dopamine receptors on astrocytes more than 25 years ago 
(Hösli and Hösli, 1986). Both anatomical and molecular studies subsequently confirmed 
the presence of D2 receptor protein and mRNA in astrocytes, including prefrontal 
cortical astrocytes (Bal et al., 1994; Khan et al., 2001). Consistent with these findings, 
stimulation of D2 receptors in astrocytic cultures with relatively high (50 μM) 
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concentrations of dopamine has been reported to increase astrocytic calcium levels 
(Parpura and Haydon, 2000). Despite the identification of functional dopamine receptors 
on astrocytes, the downstream effects of dopamine binding to these receptors remains 
largely unexplored. 
 
Glutamate Receptors. Glutamate receptors are broadly classified into two groups, 
ionotropic and metabotropic glutamate receptors. Ionotropic glutamate receptors are 
ligand-gated ion channel complexes, and include three different subtypes of receptors: 
N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), and kainate receptors. Glutamate binding to these heteromeric receptors 
results in the influx of Na+ and Ca2+. Immunohistochemical and functional studies have 
led to the conclusion that both NMDA and AMPA receptors are localized to astrocytes 
(Bowman and Kimelberg, 1984; Kettenmann et al., 1984; Conti et al., 1994; Schipke et 
al., 2001; Matthias et al., 2003; Lalo et al., 2006). 
Metabotropic glutamate receptors (mGluRs) are G protein-coupled receptors.  
These proteins are divided into Group I (mGluR1 and 5), Group II (mGluR2 and 3), and 
Group III (mGluR4, 6, 7, and 8) receptors, based on sequence similarity, pharmacology, 
and G protein-coupling. The group I receptor mGluR5 is expressed cultured astrocyte 
processes and, in vivo, in cortical astrocytes, albeit at lower levels than in observed 
cultures. (Petralia et al., 1996). However, neither mGluR1 mRNA or protein has been 
detected in astrocytes Ohishi et al. (1993) described expression of the Group II receptor 
mGluR3 mRNA in astrocytes.  Subsequent studies using an antibody that does not 
discriminate between the two different types of Group II mGluRs detected protein in 
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astrocytes (Petralia et al., 1996; Mineff and Valtschanoff, 1999).  Because mGluR2 is 
not expressed by astrocytes, it appears that the Group II mGluR found in astrocytes is 
mGluR3. Interestingly, activation of Group I and Group II mGluRs can elicit astrocyte 
motility in cultures (Lavialle et al., 2011). Functional studies have included determination 
of neuroprotective effects of Group II mGluR activation on astrocytes (Yao et al., 2005). 
Specifically, Caraci et al demonstrated, using glial conditioned media, that astrocytic 
mGluR3 activation is neuroprotective in the face of an amyloid-beta challenge (Caraci et 
al., 2011).    
 
Other Neurotransmitter Receptors. A number of other neurotransmitter receptors have  
been localized to astrocytes using immunohistochemical and functional approaches. 
These include purine receptors ( P2X7R ;Fellin et al., 2006), GABAA receptors, 
serotonin receptors (5HT5A, 5HT2B ;Carson et al., 1996; Sandén et al., 2000), α1- and β-
adrenergic receptors (Pearce et al., 1985; Aoki, 1992), muscarinic acetylcholine 
receptors using immunohistochemistry (Van Der Zee et al., 1993), and histamine H1, 
H2, and H3 receptors (Arbonés et al., 1988; Jurič et al., 2011). Interestingly, some of 
these receptors have different, even opposite effects on astrocytes than they do on 
neurons. For example, GABAA receptor activation leads to an efflux of Cl- from 
astrocytes (Fraser et al., 1995). While the functional significance of the astrocytic forms 
of neurotransmitter receptors continues to be investigated, their existence suggests that 





Astrocytes and Synapse Formation 
 
Astrocyte contributions to neuron development, and specifically to synapse 
formation, are becoming increasingly popular areas of study (Clarke and Ben A Barres, 
2013). Studies in cultured retinal ganglion cells (RGCs) show that synapse formation 
increases dramatically when these cells are cultured with astrocytes or astrocyte–
conditioned media (Ullian et al., 2001; Diniz et al., 2012). These synapses contain 
functional AMPA receptors when RGCs are cultured with neurons from the superior 
colliculus, a projection target of RGCs (Ullian et al., 2001).  Subsequent studies have 
suggested that extracellular matrix proteins elaborated by astrocytes are responsible for 
the formation of certain synapses (DeFreitas et al., 1995; Eroglu et al., 2009; Crawford 
et al., 2012). In particular, a class of astrocyte-secreted proteins known as 
thrombospondins (TSPs) are involved. The TSPs are five large extracellular matrix 
proteins involved in both cell-cell and cell-matrix interaction, acting at specific 
membrane receptors (Christopherson et al., 2005). TSP1 and TSP2 are highly 
expressed early in rodent brain development, corresponding to a period of high levels of 
synapse formation, and are down-regulated in adults (Christopherson et al., 2005). 
While the addition of TSPs alone to cultures of RGCs can induce synapse formation, 
including the formation of postsynaptic densities, these synapses contain few AMPA 
receptors and are therefore silent, suggesting that a different factor(s) may be involved 
in inducing AMPA receptor insertion into the postsynaptic density (Christopherson et al., 
2005). Further work has since determined that two more astrocytic proteins are involved 
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in synaptogenesis, hevin and SPARC: hevin is sufficient for synapse formation in RGC 
cultures (Kucukdereli et al., 2011).  
As interest in astrocytes has grown, there has been an expansion of the concept 
of synaptic signaling to include not only the presynaptic and postsynaptic neuronal 
elements, but also the astrocyte. Astrocytes are closely associated with excitatory 
synapses, enveloping excitatory pre- and post-synaptic neuronal elements (Eroglu and 
Barres, 2010). The release of neurotransmitters from astrocytes, the involvement of 
astrocytes in terminating the action of certain neurotransmitters, and the role of 
astrocytes in elaborating extracellular matrix proteins and in determining synapse 
formation, all point to gliotransmission as being an active process in neuronal signaling, 






DOPAMINE AND GLUTAMATE HYPOTHESES OF SCHIZOPHRENIA 
 
A number of hypotheses on the pathophysiological basis of schizophrenia have been 
advanced, ranging from environmental to genetic components and everything in 
between (Eyles et al., 2012; Stachowiak et al., 2013; Maziade and Paccalet, 2013; 
Schmitt et al., 2014). These hypotheses often converge on the dopamine and/or 
glutamate signaling pathways. Both the dopamine and glutamate hypotheses arose 
largely through observations of pharmacological manipulations, and have undergone 
significant refinement over the years. 
 
The Dopamine Hypothesis. The dopamine hypothesis of schizophrenia was first put 
forward in the middle of the 20th century. Following the introduction of typical 
antipsychotic drugs (APDs), a remarkable positive correlation between D2 affinity and 
the average daily dose of the APD (or plasma level of the drug) was observed, and was 
the major development responsible for the wide-spread acceptance of the dopamine 
hypothesis of schizophrenia (Creese et al., 1976; Seeman et al., 1976). As the 
dopamine hypothesis continued to develop, it appeared that the effectiveness of 
antipsychotic agents in controlling positive symptoms could be linked to their affinity for 
the D2 dopamine receptor. Further evidence for the importance of the dopamine 
receptor in the treatment of psychosis came from studies involving amphetamine, which 
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increases monoamine levels within the synapse, and can lead to psychotic symptoms 
(Peselov et al., 1985; Davidson et al., 1987). This first iteration of the dopamine 
hypothesis posited that the cause of schizophrenia was hyperdopaminergia, and that 
treatment with a dopamine receptor antagonist could relieve these symptoms.  Davis et 
al. (1991) and Deutch (1992) put forth the second version of the dopamine hypothesis, 
which suggested that positive symptoms of schizophrenia arise from an increase in 
dopamine tone in subcortical structures, including the striatum, while negative 
symptoms arise from decreased dopamine in the prefrontal cortex. Studies from several 
investigators, including both Pycock (1980) and Deutch (1990), suggested that cortical 
hypodopaminergia might lead to excessive dopaminergic activity in subcortical regions. 
 Pharmacological manipulation of PFC dopamine receptors in animal models 
causes deficits in executive functions, including processes such as working memory 
and attention Currently, an “inverted U” model suggests that PFC dopamine must be 
tightly regulated, as too much or too little dopamine leads to deficits in working memory 
(Sawaguchi and Goldman-Rakic, 1991; Arnsten 2011). The involvement of dopamine in 
PFC function suggests a central role for dopaminergic signaling in the cognitive 
symptoms of schizophrenia.  
 
The Glutamate Hypothesis. Uncompetitive NMDA receptor antagonists, such as PCP 
and ketamine, produce psychotomimetic effects in healthy control subjects, and, at 
doses that do not exert such effects in healthy control subjects. Administration of NDMA 
antagonists to schizophrenic subjects leads to an acute exacerbation of the psychotic 
process and the emergence of cognitive deficits. For example, studies as early as the 
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1960s suggested that the NMDA antagonists, PCP and ketamine, administered to 
healthy control subjects produced effects consistent with positive, negative, and 
cognitive symptoms of schizophrenia (Davies and Beech, 1960; Bakker and Amini, 
1961). More recent studies have reported that ketamine, PCP, and MK-801 result in 
cognitive deficits in a number of widespread domains, including working memory and 
executive processes, (Ghoneim et al., 1985; Oye et al., 1992; Krystal et al., 1994). 
These findings have slowly given rise to the glutamate hypothesis of schizophrenia, 
which in its current form posits that NMDA receptor hypofunction in PFC interneurons 
may contribute to the pathophysiology of schizophrenia (Homayoun and Moghaddam, 





While convincing evidence exists to support both the dopamine and glutamate 
hypotheses of schizophrenia, changes to one of these transmitter systems results in 
changes in the other (Gonzalez-Islas and Hablitz, 2003; Tseng and O’Donnell, 2004; 
Sokoloff et al., 2013; Usun et al., 2013; Yuen et al., 2013). Therefore, understanding 
interactions between these two transmitter systems will be critical to an increased 
appreciation of the pathophysiology schizophrenia and ultimately the development of 
better treatment approaches for the illness. Astrocytes may be a critical locus for 
dopamine-glutamate interactions, I hypothesize that dopamine depletion of the PFC will 
lead to significant changes in glutamate-related proteins. In particular, I posit that 
dopamine depletion will lead to alterations in the astrocytic glutamate transporter GLT-1, 
which plays a critical role in cortical glutamate uptake. In the following chapters, I will 
explore, and present data to support, this hypothesis, through the use of 









GLUTAMATE TRANSPORTER EXPRESSION FOLLOWING DOPAMINE DEPLETION 
OF THE PREFRONTAL CORTEX 
 
Excitatory amino acid transporters (EAATs) are the primary means of termination of 
glutamate signaling in the brain. Alterations in glutamate transporter levels or activity 
have been reported in a number of neurological diseases, including schizophrenia 
(Bauer et al., 2010; Rao et al., 2012). Excessive synaptic glutamate concentrations, as 
would be seen with a decrease in glutamate reuptake, can cause excitotoxicity. In the 
striatum, a loss of dopamine increases GLT-1 protein levels (Massie et al., 2010). 
Similar studies in the PFC have not been performed. In the following experiment, I 





Animals. Adult male Sprague–Dawley rats (Harlan; Indianapolis, IN) were group-housed 
with food and water ad libitum, and kept on a 12 hour light-dark cycle. All experiments 
were performed in accordance with the Guide for the Care and Use of Laboratory 




Surgical procedures. Animals underwent bilateral 6-hydroxydopamine (6-OHDA) lesions 
of the VTA, the source of the dopamine innervation of the PFC. We used this approach, 
rather than direct PFC manipulations, in order to avoid mechanical damage to the PFC 
and a resultant astrocytosis. In order to prevent uptake of 6-OHDA into noradrenergic 
axons coursing through and above the VTA, rats were injected with desipramine (12.5 
mg/kg, i.p.) 30 and 15 minutes before infusion of 1.0 µL of 6-OHDA HBr (4.0 µg/µL free 
base in 0.02% ascorbic acid at 40 C). The 6-OHDA solution was infused through a 
pump-controlled microsyringe fitted with a 33g needle at a rate of 250 nL/min at the 
following coordinates: AP: -5.4, ML: +/- 0.6, DV:  -8.4 (Paxinos and Watson, 1998). 
Sham-operated animals served as controls. Animals were sacrificed 3 weeks following 
surgery (N =6 control and 13 lesions).   
 
Catecholamine determinations. The medial PFC dorsal to the prelimbic cortex (including 
the pregenual cingulate [area 24b] and shoulder cortices; see Figure 2) was dissected 
for subsequent determination by HPLC-EC of catecholamine concentrations (Deutch 
and Cameron, 1992). 
 
Immunoblotting.  The medial PFC, including both the prelimbic (area 32) and infralimbic 
(area 25) cortices (see Figure 2), was dissected from 1.0 mm thick coronal slices and 
stored at – 80o C for up to 2 months before fractionation and subsequent immunoblot. 
Samples were subjected to a subcellular fractionation method using a series of buffers 
that contained no detergent, 1% Triton X-100, or 1%Triton/deoxycholate, yielding 
cytosolic-, membrane-, and postsynaptic density (PSD)-enriched fractions, respectively 
28	  
	  
(Gustin et al., 2010).  Samples were then mixed with sample buffer containing beta-
mercaptoethanol and heated at 65 °C for 10 minutes and separated on a 10% SDS-
polyacrylamide gel by electrophoresis. Proteins were transferred to nitrocellulose 
membranes, which were then stained with Ponceau-S and digitally scanned in order to 
compare total protein levels in each lane. 
Membranes were blocked in 4% nonfat dry milk in PBS, after which they were 
incubated in primary antibodies against GLT-1, GLAST, and EAAC1 (Table 2) in 4% 
milk in PBS overnight at 4o C. Two different GLT-1 antibodies (see Table 2) were used 
in order to confirm our results. The membranes were washed in PBS and incubated in 
appropriate peroxidase-conjugated donkey antibodies (Jackson ImmunoResearch 
Laboratories Inc; West Grove, PA).  Membranes were developed using a 
chemiluminescent protocol (Plus-ECL;Perkin-Elmer; Waltham, MA). The bands 
representing the individual proteins of interest were densitometrically scanned using 
ImageJ, and normalized to total protein levels from the Ponceau-stained membranes 












Antibody Company Antigen Catalog # Dilution 
GLT-1 Tocris amino acids 554-573 
of GLT-1 protein 
#2063 1:100k 
GLT-1 Cell Signaling 
Technologies 
C-terminus peptide #3838 1:5000 
GLAST Novus Biologicals 20aa residue C-
terminus peptide 
NB100-1869 1:3000 





Table 2. Source information and dilutions for antibodies used to examine changes in 



















Figure 2. Coronal sections illustrating the regions dissected for HPLC analysis of 
catecholamine concentrations, and for immunoblot analysis. Left) Coronal section 
indicating the prelimbic (PL) and infralimbic (IL) cortices that make up the rodent PFC, 
as well as cingulate cortex (CG1) and secondary motor cortex (M2) Right) A coronal 
section illustrating the regions used for various aspects of our experiments including 










Extent of dopamine depletion.  In our initial 6-OHDA lesion experiment, dopamine 
depletion levels were decreased by 53.3 ± 6.6% (t14= 5.83, p<0.001; Table 3). The 
dopamine concentration in the PFC of control animals averaged 1.06 ± 0.074 ng/mg 
protein. Norepinephrine concentrations (control value of 6.191 ± 0.343 ng/mg protein) 
were not significantly affected by dopamine denervation of the PFC (Table 3).  
Serotonin levels (control value of 8.743 ± 0.483 ng/mg protein) were reduced in animals 
receiving a 6-OHDA lesion by 25.2 ± 5.8% (p<0.05, Table 3). In subsequent cohorts 
prefrontal cortical dopamine concentrations in 6-hydroxydopamine-lesioned rats were 
reduced by 70.4 ± 3.6% (t17= 9.02, p<0.001; Table 3) and 59.1 ± 3.4% (t15= 4.40, 
p<0.001; Table 3). No significant change was seen in norepinephrine in either of the 
subsequent runs while serotonin was reduced in cohorts II and III by 28.9 ± 4.0% (t17= 








Dopamine Norepinephrine Serotonin 
Concentration (ng/mg protein) 
Cohort I 
Control 1.006 ± 0.087 6.191 ± 0.343 8.743 ± 0.483 
Lesion 0.485 ± 0.022 ** 5.839 ± 0.187 6.541 ± 0.509 * 
Cohort II 
Control 1.050 ± 0.086 5.137 ± 0.192 9.851 ±	 0.346 
Lesion 0.311 ± 0.039 ** 5.083 ± 0.228 6.999 ±	 0.398 ** 
Cohort III 
Control 0.459 ± 0.063 3.651 ± 0.143 7.298 ± 0.386 
Lesion 0.188 ± 0.016 ** 3.415 ± 0.112 6.102 ± 0.285 * 
 
 
Table 3. Concentrations of dopamine, norepinephrine, and serotonin in the prefrontal 
cortex following 6-OHDA lesion of the ventral tegmental area (VTA).  
---- 
** p < 0.001; * p < 0.05  
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PFC GLT-1 protein levels and dopamine depletion.  Both GLT-1 antibodies revealed a 
clear band at ~62 kDa, with a much lighter “smear” visible between 150 and 250 kDa. 
The majority of GLT-1 was seen in the membrane-enriched fraction (Figure 3). 
Following dopamine depletion, PFC levels of GLT-1 across all lesioned animals were 
increased by 240 ± 28.2% in the membrane-enriched fraction compared to control 
animals (t16=2.88, p=0.011). No changes in either GLAST or EAAC1 were observed 
(Figure 4). No differences were seen in glutamate transporter levels of any of the three 
transporters in the cytosolic- or PSD-enriched fractions. In subsequent cohorts we were 
able to achieve similar increases in GLT-1 levels of 150.0 ± 17.7% and 173.6 ± 19.4% 
using two different antibodies to GLT-1. As was demonstrated in the initial cohort, no 
changes were observed in GLT-1 in cytosol- or PSD-enriched fractions. Likewise, no 





















Figure 3. Fractionation of samples. Use of increasingly harsh detergents yields 
cytosolic-, membrane-, and post-synaptic density (PSD) –enriched fractions. GLT-1 
GLAST, and EAAC1 are primarily localized to the membrane-enriched fraction. PSD-95, 
localized to the post-synaptic density, was used as a control to verify the effectiveness 














Figure 4. The effects of PFC dopamine loss on glutamate transporter protein levels in 
the PFC. Levels of GLT-1 are significantly increased by ~240% following dopamine 
depletion, without a significant change in levels of GLAST or EAAC1.   
---- 





Dopamine in the PFC. Animals injected with 6-OHDA into the PFC averaged ~70% loss 
of dopamine relative to controls, spanning a range from 40 to 91% depletion. This rather 
variable degree of dopamine denervation is consistent with previous studies, including 
those that injected 6-OHDA directly into the PFC (Bubser, 1994; King and Finlay, 1995). 
Even when 6-OHDA is directly injected into the PFC, dopamine depletion averages only 
~80% (King and Finlay, 1995), and needle insertion causes gliosis in the region of 
interest. Gliosis, as mentioned in Chapter 2, is an activation of astrocytes and other glia 
following injury to the brain. In this study, an astrocytic response to mechanical damage 
caused by a needle being lowered into the PFC, in the form of protein increases or 
decreases, would confound results aimed at determining astrocytic protein changes that 
are a result of dopamine depletion.  Therefore, VTA lesions appear to be the most 
appropriate method of dopamine denervation of the PFC for these experiments. The 
partial dopamine denervation achieved with this method presumably reflects an inability 
to take up 6-OHDA by some dopamine neurons innervating the PFC, because of a very 
low or absent expression of the dopamine transporter (Freed et al., 1995; Sesack et al., 
1998).   
Dopamine depletion of the PFC through injection of 6-OHDA into the VTA does 
lead to dopamine depletion of other areas, such as the nucleus accumbens (>90% 
depletion) and striatum (~70% depletion). Ockham’s razor would have us believe that 
the simplest answer is the right one until proven differently. Therefore, our current 
hypothesis is that dopamine depletion of the PFC itself, rather than depletion of areas 
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projecting to the PFC, leads to increases in PFC GLT-1 levels. However, it is important 
to keep in mind that observations in the PFC may be a downstream effect of dopamine 
depletion of one of these other areas, and this idea may be worth investigating in the 
future. 
Similarly, use of 6-OHDA injections (into the prefrontal cortex or the VTA) may 
have effects that are not specific to dopaminergic cells, destroying noradrenergic or 
serotonergic axons. To prevent a loss of noradrenergic axons, animals were treated 
with desipramine to attenuate 6-OHDA uptake through the norepinephrine transporter 
(NET). We measured levels of norepinephrine and serotonin in all of our runs, and 
determined that norepinephrine levels did not change. Levels of serotonin were reduced 
in the PFC of lesioned animals, albeit to a much lower extent than dopamine (~25% 
depletion compared to ~70% for dopamine). Alternative approaches could be used to 
verify that the effect we observe is specific to dopamine depletion rather than changes 
in other transmitters. These include the use of pharmacological methods (dopamine 
receptor antagonists), or knockout or transgenic models (again targeting dopamine 
receptors, although these animals would likely need to be flox recombinant via inducible 
Cre in order to prevent developmental complications).  
 
Increases in GLT-1 following dopamine depletion. In these experiments we determined 
the levels of three glutamate transporters by immunoblot analyses of cytosolic-, 
membrane-, and postsynaptic density-enriched fractions of the PFC. All three glutamate 
transporters were most abundant in the membrane-enriched fraction.  The fractionation 
approach that we used yields fractions that are enriched in the named target, although 
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there may be trace amounts of off target proteins.  Nonetheless, this approach yields 
data that agrees well with anatomical analyses of protein localization. 
Immunohistochemical studies have found that GLT-1 and GLAST are primarily localized 
to the plasma membrane (Chaudhry et al., 1995). Furthermore, our observations are 
consistent with ultrastructural data indicating that EAAC1 is localized to both the plasma 
membrane and, to a lesser degree, the cytosol(Conti et al., 1998).  
We observed an increase in GLT-1 in the membrane-enriched fraction of 
dopamine-denervated PFC. Increases in GLT-1 levels were also observed in replicate 
experiments using two different GLT-1 antibodies.  These antibodies were both directed 
towards the C-terminus, with one antigen raised against a synthetic peptide derived 
from the amino acids 554-573 of the rat protein. The second antibody was derived from 
a different region of the C-terminus as verified by the vendor, although an exact peptide 
sequence was not disclosed. Results using these two antibodies were similar, with 
increases in GLT-1 levels of approximately 150% and 175%. The use of two antibodies 
yielding comparable results, as well as replication of the finding across multiple cohorts, 
makes us particularly confident in our findings. The increase in membrane-associated 
GLT-1 was not accompanied by any detectable change in levels of the transporter in the 
cytosolic or membrane-enriched fractions, suggesting that the increase is due to GLT-1 
protein accumulation in membranes.  
Accumulation of GLT-1 in membranes may be a response to increased 
extracellular glutamate following a loss of dopamine. Our hypothesis suggests that 
dopamine depletion leads to increases in extracellular glutamate levels and that GLT-1 
levels increase as a compensatory mechanism in an effort to prevent excitotoxic effects 
39	  
	  
that can result from prolonged increases in extracellular glutamate. However, we did not 
measure extracellular glutamate levels in our studies. Glutamate levels increase 
following dopamine depletion of the striatum (Meshul et al., 1999). Consistent with these 
findings, previous data from our lab also suggest that dopamine depletion increases 
glutamate levels in the striatum (Garcia et al., 2010). To the best of our knowledge, 
extracellular glutamate concentrations following dopamine depletion of the PFC have 
not been examined, and could be a subject for further studies. 
Studies using pharmacological disruption of dopamine signaling have reported 
that neither acute, nor chronic treatment with the D2 antagonist haloperidol changes 
extracellular glutamate levels in the PFC (Daly and Moghaddam, 1993; Yamamoto and 
Cooperman, 1994). These studies did not use no-net flux dialysis, and thus were unable 
to compare basal levels, but rather measured relative changes in response to a 
challenge to baseline levels. This led Yamamoto and colleagues (Yamamoto and 
Cooperman, 1994) to assess evoked release of glutamate.  They found that K+-elicited 
depolarization led to a non-significant trend toward an increase in PFC glutamate levels 
in rats that were chronically treated with haloperidol. Unfortunately p-values for non-
significant results were not reported in their paper; similarly, the N was not reported for 
their figure. However, all other figures included in the manuscript had an N of 5-7 rats, 
leading us to infer that the same is probably true for these results as well. Thus, it may 
be that with a larger number of animals, a significant result might have been observed.  
 
Potential for post-translational modification. Several possibilities exist to explain 
increased PFC levels of GLT-1 observed after dopamine depletion, including an 
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increase in GLT-1 gene expression (Chapter 6), an increase in astrocyte number or 
activation (Chapter 7), or changes in the turnover rate of the protein.  
Post-translational modifications can lead to changes in the function and 
localization of proteins. Our immunoblot analyses showed a clear band for GLT-1 
corresponding to ~65-70 kDa, consistent with previous reports (Schmitt et al., 2003; Zou 
et al., 2011). However, there was a faint smear of high molecular weight (150-250 kDa) 
protein species, suggesting the existence of post-translationally modified forms of GLT-
1. Analyzing these high molecular weight species, we uncovered a significant decrease 
following moderate dopamine depletion of the PFC. Previous studies have 
demonstrated that ubiquitination of GLT-1 is required for its internalization and 
subsequent degradation (González et al., 2005; Boehmer et al., 2006; Donovan and 
Poronnik, 2013). Our own observation of decreased high molecular weight species, 
coupled with these studies, suggest that accumulation of GLT-1 may be a result of 
decreased ubiquitination following moderate dopamine depletion. 
Unfortunately, our attempts to detect polyubiquitinated GLT-1 in the PFC using 
immunoprecipitation of GLT-1 and ubiquitin, as well as pull-down assays using 
ubiquitin-binding small molecules, failed. Several technical challenges make in vivo 
detection of ubiquitin difficult. Some of these include the transient nature of 
polyubiquitinated proteins, the high expression of deubiquitilyases in tissue, and the lack 
of ubiquitin antibodies with a robust immunoprecipitation profile. Thus, while difficult to 
demonstrate in vivo, we speculate that decreases in ubiquitination, and the subsequent 
degradation, of GLT-1 may explain accumulation of GLT-1 protein in membrane-





DOPAMINE DEPLETION EXTENT REVEALS DIFFERENTIAL  
EFFECTS ON GLT-1 
 
In Chapter 4, we observed that dopamine denervation of the PFC increases levels of 
the glutamate transporter GLT-1, but not the two other cortical transporters, GLAST and 
EAAC1. Although there is a significant overall increase in membrane-associated GLT-1, 
we noticed that the distribution of GLT-1 levels in the individual animals followed what 
appeared to be a bimodal distribution. We therefore determined whether there was a 
correlation between the extent of dopamine depletion and the magnitude of the increase 
in GLT-1. A significant negative correlation was uncovered (r=0.77, p < 0.01; Figure 5). 
When we examined the scatterplot illustrating the correlation, we noticed that the 
lesioned animals appeared to fall into two groups with a separation at approximately 
65% dopamine depletion. We therefore did a post-hoc analysis examining GLT-1 levels 
in cohort II animals described in Chapter 3, with “moderate” depletions of 40-65% of 
control values, and “severe” depletions of >65% dopamine depletion. 
Dopamine levels were reduced by 58.0 ± 3.2% in “moderate” depletion animals, 
while animals with the more extensive “severe” depletions averaged 78.9 ± 2.5% 
dopamine depletion compared to controls (Table 4). Norepinephrine levels were 




















Figure 5. Negative correlation between extent of dopamine depletion and changes 
observed in GLT-1 levels. As dopamine depletion becomes more “severe” GLT-1 levels 
appear comparable to control levels.  
--- 
r = -0.77  p <0.01 



















Dopamine Norepinephrine Serotonin 
Concentration (ng/mg protein) 
Control 1.050 +/- 0.086 5.137 +/- 0.192 9.851 +/- 0.346 
Moderate Depletion 
(40-65%)  0.440 +/- 0.035 * 5.612 +/- 0.447 8.106 +/- 0.378 * 
Severe Depletion 
(>65%) 0.219 +/- 0.026 * 4.704 +/- 0.103 6.209 +/- 0.425 * 
 
 
Table 4. Neurotransmitter concentrations following separation of animals in cohort II by 
the extent of dopamine depletion. ANOVA analysis revealed significant decreases in 
both dopamine depletion groups compared to controls and a decrease in serotonin 
levels in animals with a severe dopamine depletion. 
---- 





A one-way between subjects ANOVA (F2,16 = 24.03, p < 0.001 ) revealed that serotonin 
levels were significantly decreased in both the “moderate” and “severe” depletion 
groups relative to controls (Table 4).  
The extent of PFC dopamine depletion had a significant effect on GLT-1 (F2,16 = 
27.74, p < 0.001; Figure 6). Post-hoc comparisons using the Tukey test indicated that in 
animals sustaining moderate PFC dopamine depletion, there was a marked increase in 
GLT-1 levels (see Figure 6). In contrast, there was no significant difference in GLT-1 
levels, relative to controls, in animals with the more extensive (“severe”) dopamine 
depletion (see Figure 6). Furthermore, no changes were observed in GLAST or EAAC1 
in either the “moderate” or “severe” dopamine depletion groups compared to controls 
(Figure 6). Post-hoc analyses using these “moderate” and “severe” dopamine depletion 
groups in prior experiments, as well as subsequent studies, were consistent with 














Figure 6. Glutamate transporter changes as a function of severity of dopamine 
depletion. Lesioned animals were separated based on the extent of dopamine 
depletion, with “moderate” depletion being classified as 40-65% dopamine loss, and 
“severe” dopamine depletion being characterized by >65% dopamine loss in the PFC. 
Animals with a “moderate” depletion showed an almost 400% increase in GLT-1 levels 
while “severe” depletion resulted in normal levels of GLT-1. No significant changes were 
observed in GLAST or EAAC1 in either group. 
---- 







 We demonstrated previously that dopamine depletion of the PFC leads to 
significant increases in protein expression of GLT-1 across all lesioned animals (see 
Figure 4). However, when animals are separated based on the extent of PFC dopamine 
depletion into “moderate” and “severe” depletion groups, only animals with moderate 
depletion display significantly increased levels of GLT-1. This finding is particularly 
striking as it suggests that different mechanisms are activated, depending on the extent 
of dopamine depletion.  
In subsequent replications of our finding that only moderate PFC depletion elicits 
an increase in GLT-1 protein levels, we used two different methods of injecting 6-OHDA 
in an attempt to obtain the full range of cortical dopamine depletion. One was the 
original approach, in which a microsyringe with a 33 gauge needle was mounted in a 
pump apparatus to continuously eject the 6-OHDA solution. We also used a procedure 
in which the plunger of a microsyringe equipped with a 23 gauge needle was advanced 
manually; this would presumably result in a somewhat larger extent of diffusion of 6-
OHDA. We found that the pump method usually produced less severe depletions than 
the manual method, although there was some overlap in the magnitude of depletion 
(Figure 7).  
VTA lesions by 6-OHDA injection can have effects on other neurotransmitters, 
such as norepinephrine and serotonin. In this experiment norepinephrine levels were 





















Figure 7. Different methods of 6-OHDA delivery result in different extents of PFC 
dopamine loss. Manual injections consistently resulted in more severe dopamine 
depletion when compared to injections using the microsyringe/pump. Both methods 
were used in order to observe a varied extent of dopamine depletion. 
---- 




serotonin levels were significantly reduced in lesioned animals compared to controls. 
Therefore, we cannot rule out the possibility that serotonin may play a role in the 
differential effects observed in these two groups of lesions. Future studies that could 
address this possibility will be discussed in greater detail in Chapter 11.  
We have posited that dopamine depletion leads to increases in PFC glutamate, 
based on studies performed in the striatum. No studies have shown the effects of 
dopamine depletion on glutamate levels in the PFC. Future studies addressing this may 
be valuable not only to our own studies but to the field of researchers studying the 
interactions between dopamine and glutamate within the PFC. 
 
Differential effects following dopamine depletion. There are several examples of 
differential changes in proteins, behavior, and mRNA following manipulation of the 
nigrostriatal pathway (Arbuthnott and Ungerstedt, 1975; Nisenbaum et al., 1996; Paillé 
et al., 2010). For example, “partial” striatal dopamine depletion (~75%) increases levels 
of the NMDA receptor subunit GluN2A (NR2A), while no change in GluN2A occurs 
following “full” (>95%) dopamine depletion (Paille et al., 2010). Interestingly, decreases 
in GluN2B (NR2B) were observed only in animals with a “full” dopamine depletion 
(Paille et al., 2010).  
Arbuthnott and Ungerstedt (1975) demonstrated that with lower levels of 
electrical stimulation (reported as uColoumbs) of the nigrostriatal pathway (electrodes 
placed at the following coordinates AP= -4.0, ML= 1.7, DV= 7.6) in rats, sniffing 
behavior was induced, but at higher stimulation levels rotational behavior was observed 
(Arbuthnott and Ungerstedt, 1975).  
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In another study, direct injection of 6-OHDA into the striatum led to significant 
changes in mRNA levels encoding for preprotachykinin (PPT) and preproenkephalin 
(PPE)  (Nisenbaum et al., 1996). Striatal PPT gene expression was significantly 
reduced regardless of depletion extent. However, when enkephalin mRNA levels were 
evaluated relative to the extent of dopamine depletion, significant increases in PPE 
gene expression enkephalin mRNA were only observed in animals with greater than 
90% dopamine depletion, suggesting that different processes may be induced 
depending on the extent of dopamine depletion. These examples suggest that 
differential responses that are dependent on the extent of dopamine loss occur at the 
level of protein, behavior, and genes.  
The mechanism through which somewhat less extensive PFC dopamine 
depletions increase GLT-1 levels, but greater degrees of dopamine depletion do not 
elicit any detectable change in GLT-1 levels, is not known.  The decreases in GluN2B 
described by Paille and colleagues following extensive dopamine loss in the striatum 
raises the interesting possibility that alterations in this or other proteins involved in 
glutamate signaling may be responsible for a neuronal compensatory response 
following extensive dopamine depletion of the PFC in our animals. Thus, another 
possible explanation for the differential response to varying extents of dopamine 
depletion in the PFC is that following moderate dopamine depletion, GLT-1 increases 
reflect an astrocytic compensatory response to increased extracellular glutamate, but 
that more severe dopamine depletion elicits a neuronal response. This idea will be 





GLUTAMATE TRANSPORTER GENE EXPRESSION FOLLOWING DOPAMINE 
DEPLETION OF THE PREFRONTAL CORTEX 
 
Dopamine depletion of the prefrontal cortex leads to an increase in levels of the 
glutamate transporter GLT-1 but not the two other cortical glutamate transporters, 
GLAST and EAAC1. The increase in membrane-associated GLT-1 in the PFC may be 
due to a selective increase in GLT-1 but not GLAST or EAAC1 mRNAs. We therefore 
examined the relative abundance of the mRNAs encoding the three cortical glutamate 




The methods used in this experiment are the same as described in Chapter 4, with the 
exception that we used RT-PCR to assess glutamate transporter gene expression 
instead of monitoring protein levels.   
 
RT-PCR. The prelimbic and infralimbic PFC was dissected (control N=12; 6-OHDA 
N=12) and stored at -80°C. RNA was extracted from the tissue using an RNeasy Mini kit 











Table 5. Primers designed using NCBI-Primer Blast 
 
  
Gene Forward (5’-3’) Reverse (5’-3’) 
GLT-1 ATGCCGCACACAACTCTGTCGT TCAGCTGACTTTCCATTGGCCGC 
GLAST CCTCAGGCCGGTCTAGTCACCA GGTGGTGGTTCGGAGGCGGT 
EAAC1 CTTCCTGCGGAATCACTGGCTG GAGCTCACTGTGTCCTCGAACC 
GAPD
H GGGCTCTCTGCTCCTCCCTGT CCAGGCGTCCGATACGGCCA 
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cDNA synthesis was performed using Superscript Vilo reverse transcriptase (Life 
Technologies; Grand Island, NY). RT-PCR was performed with SYBR Green master 
mix (Bio-Rad; Hercules, CA) as the reporter using the primers described in Table 5.  
Primers were designed using NCBI-Primer Blast. All primers were optimized for 60 
degree annealing and two-step cycling was performed from 95 degrees (10s) to 60 
degrees (30s) for 40 cycles. Melting curves were inspected after every run performed 
on BioRad CFX96 real time cyclers. Cycle threshold values were subjected to statistical 





Extent of dopamine depletion.  The dopamine concentration in the PFC of control 
animals averaged 0.49 ± 0.05 ng/mg protein. Prefrontal cortical dopamine 
concentrations in 6-hydroxydopamine-lesioned rats were reduced across all lesioned 
subjects by 74.29 ± 5.1% (t27= 7.36, p<0.001). Norepinephrine concentrations (control 
value of 4.34 ± 0.25 ng/mg protein) were significantly reduced by 29.9% after dopamine 
denervation of the PFC (t27=2.92, p<0.01). Serotonin levels were unchanged (See Table 
6). We also analyzed mRNA levels in animals separated into moderate and severe 
dopamine depletion groups, as described in Chapter 4.  The average decrease in PFC 
dopamine concentrations was 50.27% in the moderate group, and 89.6 % depletion in 
the severe group (Table 6). Norepinephrine levels were unchanged in the “moderate” 
dopamine depletion group, while levels of norepinephrine were reduced by 28.85 ±6.8% 
in the “severe” dopamine depletion group (Table 6). Similar to the combined depletion 
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groups, serotonin levels remained unchanged when animals were separated by 
dopamine depletion extent (Table 6). 
 
Glutamate transporter mRNA levels. Real-time PCR revealed no significant change in 
mRNA levels of any of the glutamate transporters examined (GLT-1, GLAST, and 
EAAC1) in response to DA depletion across all animals (Figure 8).  Similarly, when 
evaluated based on the extent of dopamine depletion, no changes were observed in 
relative abundance of the mRNAs for GLT-1, GLAST, and EAAC1 in animals with 










































Dopamine Norepinephrine Serotonin 
Concentration (ng/mg protein) 
Control 0.497 +/- 0.050 4.338 +/- 0.252 6.958 +/- 0.422 
All Lesioned 
Animals 0.128 +/-0.025 * 3.162 +/- 0.344 * 5.386 +/- 0.493 
Moderate Depletion 
(40-65%)  0.247 +/- 0.013 * 4.318 +/- 0.269 5.644+/- 0.733 
Severe Depletion 
(>65%) 0.052 +/- 0.014 * 2.266 +/- 0.276 * 5.222 +/- 0.682 
 
 
Table 6. Concentrations of dopamine, norepinephrine, and serotonin in the prefrontal 
cortex of animals for RT-PCR analysis following 6-OHDA lesion of the ventral tegmental 
area. HPLC analysis uncovered significant decreases between control and lesion 
animals in both dopamine and norepinephrine in the PFC, but not in serotonin. When 
animals were separated by the extent of dopamine depletion, animals with severe 
depletion had significantly reduced norepinephrine levels, while animals with moderate 
depletion showed no change. Separation of animals into moderate and severe depletion 
did not reveal any differences in serotonin levels 
---- 
























Figure 8. No change was observed in mRNA expression levels of GLT-1, GLAST or 






No changes in the relative abundance of GLT-1, GLAST, or EAAC1 mRNA levels were 
seen in the PFC of dopamine-depleted compared to control animals. Similarly, 
separating animals into moderate and severe cortical dopamine denervation groups did 
not reveal a difference in mRNA levels across groups. The large increase in GLT-1 
protein levels that we observed in response to cortical dopamine denervation without a 
concurrent increase in steady-state mRNA levels suggests that the increase in GLT-1 
protein is not due to de novo itranscription of the transporter.    
         Schmitt et al. (2003) reported that chronic treatment with the D2 receptor 
antagonist haloperidol decreases GLT-1 mRNA in the PFC. In contrast, we did not 
observe a change in GLT-1 gene expression after cortical dopamine depletion. The 
difference between our results and those of Schmitt and colleagues may be attributable 
to the fact that the dose of haloperidol used by Schmitt et al. results in complete 
occupancy of D2 receptors in vivo (see Perez-Costas et al., 2008), whereas our lesions 
resulted in an incomplete dopamine denervation, even in what we designate the 
“severe” depletion group. Furthermore, rather than preventing dopaminergic signaling at 
all dopamine receptors, haloperidol has a high affinity only for D2 receptors (including 
D2, D3, and D4), whereas dopamine depletion disrupts signaling through D2 but also D1 
receptors, which are expressed at higher density in the PFC than D2 family receptors.   
 Another possibility is that decreases in norepinephrine levels observed in our 
samples, which were not observed when assessing protein levels of the transporters 
(see Chapters 4 and 5), may lead to a differential response. However, when lesioned 
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animals are separated into moderate and severe dopamine depletion groups, the 
moderate depletion group closely resembles animal cohorts used in the immunoblot 
studies. Thus, differences in norepinephrine levels do not explain the differential 
regulation of GLT-1 protein and mRNA expression.  
 Another explanation for the lack of an observed increase in GLT-1 mRNA levels 
is that levels of mRNA actually do increase following dopamine depletion, but we fail to 
capture this increase at our three-week post-surgery timepoint. The half-life of GLT-1 
protein is suggested to be approximately 24 hours (Zelenaia and Robinson, 2000). 
Therefore, it seems unlikely that an elevation in protein levels would be observed 
without detection of a concurrent increase in mRNA levels, if increases in transcript 
levels are responsible for increases in protein levels. These experiments, therefore, 
suggest that increases in GLT-1 protein levels are not due to increases in protein 
production as predicted by mRNA levels. Two more possible explanations for the 
increase in GLT-1 observed following dopamine depletion are examined in subsequent 








ASSESMENT OF ASTROCYTE NUMBER AND ACTIVATION 
 
In Chapter 4, I demonstrated that a significant increase in GLT-1 occurs as a 
result of dopamine depletion. Three possibilities were put forward that may explain the 
increase in GLT-1 levels, including gene expression, an increase in astrocyte number or 
activation and decreased protein degradation. In Chapter 6, we tested the hypothesis 
that increases in GLT-1 are a result of increased gene expression, and observed that 
mRNA levels of GLT-1 did not change following dopamine depletion. These 
experiments showed that increased GLT-1 protein levels seen after PFC dopamine 
depletion were not attributable to increased GLT-1 gene expression. In the current 
chapter, I discuss experiments designed to explore the possibility that dopamine 
depletion of the PFC leads to an increase in astrocyte number or activation, increasing 
GLT-1 protein levels. 
 Gliosis refers to the response of glial cells to brain injury. Astrogliosis refers to a 
number of changes in astrocytes, including alterations in morphology, gene and protein 
expression, astrocyte function, and astrocyte number (Pekny et al., 2014). Astrogliosis 
can occur in response to neurodegenerative conditions, as well as more acute 
conditions such as stroke (Tilleux and Hermans, 2007; Li et al., 2008). Classically, 
reactive astrocytes that invade an area of acute damage or inflammation show an 
increase in the extent of their processes and increased levels of certain proteins, such 
as the astrocytic marker glial fibrillary acidic protein (GFAP; Pekny and Pekna, 2004; 
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Bramanti et al., 2010). In an effort to determine whether changes in GLT-1 occur 
because of an increased number, or activation, of astrocytes, we measured GFAP 
levels in the PFC by immunoblot, and determined the number GFAP-immunoreactive (-





Immunoblotting.  Tissue preparation, immunblotting, and analysis was performed as 
described in Chapter 4. An antibody generated against GFAP was used at a 1:1000 
dilution (Chemicon, #1540), using a donkey anti-rabbit antibody and ECL detection. 
 
Stereology.  The number of GFAP-immunoreactive (-ir) positive astrocytes in the PFC of 
sham-lesioned animals (n=4) and animals receiving 6-OHDA lesions of the VTA (n=4) 
was determined using the optical dissector stereological method (2500 µm2 sampling 
area; MBF Bioscience; Williston, VT) on serial sections collected through the extent of 
the PFC and immunostained with the previously described GFAP antibody. The number 
of sampling regions varied by section but ranged between 10-20 regions of interest 
(ROIs)/hemisphere/section. The activation of astrocytes, as reflected by branching 
complexity, was determined by measuring the number of GFAP-ir processes crossing 







GFAP expression. Western blot analysis failed to reveal a change in PFC levels of the 
astrocytic marker GFAP across all lesioned animals or in animals separated into 
moderate and severe PFC dopamine depletion groups (see Figure 9). 
 
Astrocyte number and morphology. Consistent with the lack of change in GFAP levels, 
stereological studies found no change in the number of PFC astrocytes after dopamine 
denervation of the PFC (Figure 10). Because the dopamine innervation of the PFC is 
more dense in layer V than layers II/III (Kalsbeek et al., 1988), we also looked for a 
lamina-specific change in astrocyte number after dopamine denervation; there was no 
change (Figure 10). Similarly, we did not observe an increase in the number of GFAP-ir 










Figure 9. A) Representative blots of GFAP. B) Immunoblot assessment revealed that 












Figure 10. Assessment of astrocyte number and activation. A) Representative images 
of GFAP staining of the PFC from a control (left) and a lesioned animal (right); scale bar 
=50 µm B) Stereological methods failed to reveal a difference in total astrocyte number 
in the PFC. C) Similarly, analysis of only deep layers (V/VI) of the PFC failed to reveal a 
significant change in astrocyte number. D) Assessment of astrocyte activation did not 









It is common for gliosis to occur in areas surrounding a site of injection into the brain. In 
an effort to prevent an astrocytic response to mechanical damage we injected 6-OHDA 
into the A10 dopamine cell group in the VTA, which is the sole source of the dopamine 
innervation of the PFC. The results are not consistent with an increased number of 
astrocytes or astrocytic processes contributing to the dopamine denervation-induced 
increase in GLT-1 levels in the PFC.   
 Immunoblot analysis failed to reveal a significant change in GFAP protein levels 
following dopamine depletion. Even when animals were separated into moderate (40-
65%) and severe (>65%) dopamine depletion groups, no differences were observed 
when compared to control animals. GFAP is a commonly utilized marker of astrocytes, 
and its expression is increased in reactive astrocytes (Pekny and Pekna, 2004). 
Therefore, these data suggest that there is not an increase in PFC astrocyte number or 
reactivity following dopamine depletion.  
 To further verify our imunnoblot data, we performed stereological assessment of 
GFAP positive cells in the prefrontal cortex, observing no difference between control 
and dopamine-denervated animals. Furthermore, existing astrocytes do not display 
increased reactivity as measured by GFAP levels and astrocyte branching complexity. 
Thus, despite an astrocytic response to dopamine depletion of the PFC as reflected by 
increased levels of GLT-1, increases in GLT-1 cannot be attributed to morphological 
changes in astrocytes. Three possible explanations for increased levels of GLT-1 
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protein expression following dopamine depletion were identified in the discussion of 
Chapter 4: increased gene expression, increased astrocyte number or reactivity, and 
decreased GLT-1 degradation. Thus far, I have shown that gene expression and 
astrocyte number or activation, are not responsible for increased GLT-1 protein levels. 
In the following chapter, I will explore the effects of dopamine depletion on glutamate 
uptake in an effort to determine whether glutamate transporter activity increases in 






GLUTAMATE UPTAKE IN THE PREFRONTAL CORTEX  
FOLLOWING DOPAMINE DEPLETION 
 
We have seen that dopamine denervation of the prefrontal cortex increases GLT-
1 protein levels, specifically in those animals with moderate (40-65%) PFC dopamine 
depletion. This change cannot be attributed to an increase in GLT-1 gene expression, 
nor to an increase in astrocyte number or astrocyte activation. Just as increases in gene 
expression do not always lead to increased protein expression, increases in protein 
levels do not always lead to increases in protein function. GLT-1 is the primary 
mechanism for glutamate uptake in the cortex. Although we observed an increase in 
levels of GLT-1, the exact stoichiometry of GLT-1 protein:glutamate transport is not 
known.  In the current chapter I explore the effects of dopamine depletion on glutamate 




The methods used in this experiment are the same as described in Chapter 4, with the 
exception that we assessed high affinity uptake of radiolabeled glutamate in PFC tissue 




Glutamate Uptake Assay. Animals were deeply anesthetized, sacrificed, and their 
brains removed. The prelimbic and dorsal infralimbic cortices were dissected on ice. 
Tissue was minced using a razor blade and suspended in Krebs Ringer Hepes buffer 
(120 mM NaCl, 4.7 mM KCl, 1.2 mMKHPO4, 10.0 mM HEPES). 250 µL of the tissue 
suspension was added to 250 µL of KRH buffer in glass tubes. Samples were then 
heated to a 37 °C water bath shaking at 100 rpm. 50 µL of [3H] glutamate (10 nM 
radiolabelled and 90 nM unlabelled glutamate) was added to samples, which were 
incubated for 10 minutes at 37 °C under constant agitation. On a Brandell filter 
apparatus, uptake was terminated by filtration through a GF/B Whatman filter pre-
soaked in 0.3 % PEI (poly-ethyleneimine) in water, washing 3 times with ice-cold PBS. 
Filters were incubated with 7 mL scintillation liquid Ecoscint H overnight on rotary 
shaker at temp (37°C or room temp). Each sample was run in triplicate. In order to 
determine non-specific uptake, the same procedures were followed, except that 
samples were kept at 4°C rather 37°C. Non-specific uptake was subtracted from values 
observed at 37°C. Averages of the three replicates were determined and adjusted for 
non-specific up-take. Protein concentrations of individual samples were determined 




Neurotransmitter levels.  The dopamine concentration in the PFC of control animals 
averaged 0.67 ± 0.05 ng/mg protein. Prefrontal cortical dopamine concentrations across 
all 6-hydroxydopamine-lesioned rats were reduced by 63.2 ± 6.3% (t16= 7.62, p<0.001). 
67	  
	  
ANOVAs were conducted to compare the effect of dopamine depletion on dopamine, 
norepinephrine, and serotonin concentrations in control, moderate and severe 
dopamine depletion conditions. Significant main effects were observed for all three 
monoamines:  dopamine: F2,15 = 181.0, p < 0.001, norepinephrine: F2,15 = 5.546, p = 
0.016, and serotonin: F2,15 = 15.21, p < 0.001. Tukey multiple comparison tests were 
used to compare concentration differences across dopamine depletion groups. The 
severe depletion group had significantly reduced dopamine concentrations compared to 
the moderate depletion group (Table 7). Norepinephrine levels were significantly 
reduced in the severe dopamine depletion group, while the moderate dopamine 
depletion group showed no significant difference from controls. Similarly, serotonin 
levels were significantly reduced in the severe but not moderate dopamine depletion 
group, compared to controls, (Table 7). 
 
Glutamate Uptake. No significant change in glutamate uptake was observed when all 
lesioned animals were compared to controls (Figure 11A). However, when data from 
animals with moderate and severe dopamine depletions were compared to control 
subjects by ANOVA, a significant effect of dopamine depletion on glutamate uptake was 
uncovered (F2,15 = 7.33, p = 0.006; Figure 11A).  Post-hoc analysis with the Tukey test 
found that glutamate uptake in animals with severe dopamine depletions was 
significantly greater than uptake in control rats (Figure 11B); No such difference was 
observed comparing glutamate uptake in animals with moderate PFC dopamine loss to 

















Dopamine Norepinephrine Serotonin 
Concentration (ng/mg protein) 
Control 0.716 +/- 0.059 6.776 +/- 0.539 10.13 +/- 0.322 
All Lesioned 
Animals 0.298 +/-0.051 * 3.345 +/- 0.843 * 8.758 +/- 0.459 
Moderate Depletion 
(40-65%)  0.464 +/- 0.015 * 4.368 +/- 1.211 10.070+/- 0.408 
Severe Depletion 
(>65%) 0.160 +/- 0.032 * 2.493 +/- 1.145 * 7.665 +/- 0.367 * 
 
Table 7. Concentrations of dopamine, norepinephrine, and serotonin. Significant 
decreases were observed in dopamine and norepinephrine when all lesions were 
examined together, however, no change was observed in serotonin. When separated 
into moderate and severe dopamine depletion groups both groups showed significant 
reductions in dopamine levels, while only the severe dopamine depletion group 
exhibited decreased norepinephrine and serotonin levels. 
---- 




Figure 11. Glutamate uptake was assessed in tissue from the PFC using tridiated 
glutamate. A) No difference was seen in lesions as a whole. B) Separation of animals 
into moderate and severe depletion groups revealed a significant increase in glutamate 
uptake in animals with a severe dopamine depletion (* = p <0.05). C) When glutamate 
uptake was compared to dopamine depletion a significant correlation was observed (r = 
0.494 p=0.04).  
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These results can be better appreciated when comparing the relationship between 
extent of dopamine depletion and high affinity glutamate uptake: a significant correlation 




High affinity glutamate uptake was increased in the PFC of animals with cortical 
dopamine loss, but only if the extent of dopamine depletion exceeded about 70%. 
Interestingly, the relationship between glutamate uptake and extent of dopamine 
depletion is different than the relationship between GLT-1 protein levels and extent of 
cortical dopamine loss.  In the latter case, only animals with moderate degrees of 
dopamine depletion showed an increase in membrane-associated GLT-1 levels, but the 
activity of the transporter (glutamate uptake) was increased only in animals with 
extensive PFC dopamine loss. Thus, it appears that increases in membrane-bound 
GLT-1 protein levels are not accompanied by an increase in functional protein, but 
rather an accumulation of non-functional protein. This further suggests the importance 
of understanding whether post-translational modifications to GLT-1 occur following 
dopamine depletion, as discussed in Chapter 5. In addition, it will be important to 
determine whether these changes are dependent upon the extent of depletion, which 
may explain differences in GLT-1 levels and glutamate uptake between “moderate” and 




Neurotransmitter levels. The effects of VTA lesions on dopamine concentration are 
similar to results of previous experiments discussed in this thesis, i.e., a significant 
decrease in dopamine levels as a whole. The magnitude of this decrease was 
somewhat lower (~63% depletion) as compared to previous experiments (~70% 
depletion). Interestingly, when separated into moderate and severe depletion groups the 
average dopamine depletion of the moderate depletion group was ~43% compared to 
the ~50% depletion seen in previous experiments. The average depletion in the severe 
dopamine depletion group (~80%) was similar to that reported in previous studies 
(~78%). Finally, decreases were observed in norepinephrine and serotonin levels in the 
severe depletion group but not in the moderate depletion group. As was mentioned in a 
previous chapter, the simplest explanation for changes resulting from a VTA lesion is 
likely to be due to decreases in dopamine concentrations. Dopamine depletion has 
been shown to have an effect on GLT-1 protein expression in the striatum (Massie et al. 
2010), while to the best of our knowledge the effect of norepinephrine and serotonin 
manipulation on GLT-1 expression has not been investigated. Studies examining these 
effects may prove useful in the future if differential responses in GLT-1 function and 
expression between moderate and severe depletion groups cannot be explained solely 
through the effects of dopamine depletion.  
 
Glutamate transporter contributions to glutamate uptake. Keeping samples on ice is an 
effective method to stop transport by all three glutamate transporters. This method was 
used with the understanding that >90% of glutamate uptake in the cortex occurs through 
GLT-1. However, our glutamate uptake data appears to contradict our protein 
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expression findings, with increased uptake in the severe depletion group, which did not 
show elevated changes in GLT-1 protein levels. One possibility is that another of the 
transporters has significantly increased function, while protein expression remains 
unchanged. This data suggests that further investigations of glutamate uptake are 
warranted. Specifically, separating the relative contributions to glutamate uptake made 
by the individual transporters GLT-1, GLAST, and EAAC1, may shed light on the effects 
of dopamine depletion on glutamate uptake. This could be done using transporter-
specific inhibitors. Previous studies have shown that EAAC1 is upregulated following 
knockdown of GLT-1 expression (Salvatore et al., 2012).  
 Across all lesioned animals there was no significant change in glutamate uptake. 
However, when separated by extent of dopamine depletion, animals with more severe 
dopamine depletion exhibited higher rates of glutamate uptake. This suggests that a 
mechanism separate from the increased GLT-1 expression observed in animals with 
moderate dopamine depletion, may lead to increased glutamate uptake following more 
extensive dopamine depletion. Possible neuronal mechanisms are examined in 








ALTERATIONS IN EXPRESSION OF GLUTAMATE-RELATED PROTEINS 
FOLLOWING DOPAMINE DEPLETION OF THE PREFRONTAL CORTEX 
 
In Chapter 4, I discussed the effect of dopamine depletion on glutamate transporters 
within the prefrontal cortex, and suggested that these changes are in response to 
increased extracellular glutamate levels. The glutamate transporters are but one of a 
variety of mechanisms that contribute to glutamate homeostasis. In this chapter, I will 
discuss a number of glutamate-related proteins, including ionotropic NMDA and AMPA 
receptor subunits, the cystine/glutamate antiporter subunit xCT, and group II 
metabotropic glutamate receptors.  
 
Ionotropic glutamate receptors. Ionotropic glutamate receptors, including NMDA and 
AMPA receptors, are primarily localized to postsynaptic terminals. However, expression 
of NMDA and AMPA receptors on astrocytes has also been reported (Bowman and 
Kimelberg, 1984; Kettenmann et al., 1984; Conti et al., 1994; Schipke et al., 2001; 
Matthias et al., 2003; Lalo et al., 2006). Both AMPA and NMDA receptors are critical for 
the establishment of long-term potentiation, which is a long lasting increase in the 
strength (or transmission) of a synapse. Binding of glutamate to these receptors causes 
a depolarization of the postsynaptic membrane through the transport of Na+ and Ca2+ 
into the cell. 
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AMPA receptors are made up of several subunits, including GluA1, GluA2, GluA3, and 
GluA4. These subunits form heterotetramers that typically consist of two GluA2 subunits 
along with a dimer of one of the other three subunits (Shepherd and Huganir, 2007). 
The presence of GluA2 subunits generally renders AMPA receptors impermeable to 
calcium (Burnashev et al., 1992).  
NMDA receptors also consist of a heterotetramer of subunits, including two 
GluN1 and two GluN2 subunits. Eight splice variants of GluN1 exist, however GluN1-1a, 
is the predominant GluN1 isoform found in the prefrontal cortex (Paoletti et al., 2013). 
The GluN2 subunit has four variants labeled A through D, with GluN2A and GluN2B 
being the most common variants in the adult rodent PFC (Paoletti et al., 2013). The 
GluN2 subunit present in the heterotetramer confers biophysical function to the receptor 
(Wyllie et al., 2013).   
In order to gain a better understanding of changes in glutamate systems after 
cortical dopamine denervation, I analyzed protein levels of ionotropic glutamate receptor 
subunits from both the NMDA receptor (GluN1, GluN2B) and the AMPA receptor 
(GluA1, GluA2), following dopamine depletion.  
 
Cystine/Glutamate antiporter system. I previously discussed System xC- in Chapter 2. 
This antiporter system exchanges intracellular glutamate for extracellular cystine in a 
1:1 stoichiometry. The subunit xCT confers substrate specificity to the antiporter.  
 
Group II metabotropic glutamate receptors. Group II metabotropic glutamate receptors 
are primarily considered to be presynaptic proteins.  However, one of the Group II 
75	  
	  
receptors, mGluR3, is also localized to astrocytes (Ohishi et al., 1993; Petralia et al., 
1996). On the presynaptic terminal, group II mGluRs couple to inhibitory G-proteins to 
inhibit glutamate release. The functional effect of astrocytic mGluR3 remains poorly 
defined. Emerging evidence suggests that activation of mGluR3 in astrocytic cultures 
may lead to increases in GLT-1 protein expression (Aronica et al., 2000). 
 
In this chapter, I explore the effects of dopamine depletion on a number of glutamate-
related proteins with differing localizations, ranging from presynaptic to postsynaptic to 
astrocytic. By using HPLC-EC determination of dopamine depletion extent followed by 
immunoblot analysis, I was able to determine whether changes in glutamate-related 





The methods of this chapter are the same as those used in Chapter 4, with the 
exception of the antibodies used (see Table 8). I attempted to use antibodies against 
mGluR2 and mGluR3 specifically but was not satisfied with the specificity of these 
















Antibody Company Antigen Catalog # Dilution 
GluN1 Millipore C-terminus peptide 
aa 900-938 
AB9864 1:2000 
GluN2B BD Biosciences C-terminus peptide 
aa 891-1051  
#610417 1:500 
GluA1 Millipore Cytoplasmic domain 
peptide 
AB1504 1:1000 
GluA2 Millipore C-terminus peptide AB1768 1:500 
mGluR2/3 Millipore C-terminus peptide: 
NGREVVDSTTSSL 
AB1553 1:1000 
xCT Novus Biologicals N-terminus peptide  NB300-318 1:1000 
xCT Abcam 50 aa N-terminus 
peptide 
Ab37185 1:1000 
xCT David Baker  -- 1:500 
xCT Santa Cruz N-terminus sc-79359 1:1000 
 






Extent of dopamine depletion.  The dopamine concentration in the PFC of control 
animals averaged 1.05 ± 0.085 ng/mg protein. Prefrontal cortical dopamine 
concentrations in 6-hydroxydopamine-lesioned rats were reduced by 70.4 ± 3.6% (t17= 
9.02, p<0.001). Norepinephrine concentrations (control value of 5.137 ± 0.192 ng/mg 
protein) were not significantly affected by dopamine denervation of the PFC (t17=0.16, 
NS).  Animals were further separated into moderate and severe depletion groups, with 
moderate depletion being those animals with dopamine depletions of 40-65% and 
severe depletion being those animals with depletions greater than 65%. For more 
detailed information, please refer to Table 6 in Chapter 5. 
 
No effect on NMDA or AMPA receptor subunit expression. Antibodies selective for 
GluN1 and GluN2B detected distinct bands at 116 and 108 kDa, respectively. The 
majority of protein expression for these proteins was observed in the PSD-enriched and 
membrane-enriched fractions, respectively (Figure 12A). Levels of GluN1 and GluN2B 
in their respective fractions were not affected by dopamine depletion when all lesioned 
animals were analyzed together (Figure 12B), nor were differences seen when animals 
were divided into moderate and severe depletion groups (Figure 12B). 
Antibodies against AMPA receptor subunits GluA1 and GluA2 detected bands at 
106 and 99 kDa, consistent with their predicted masses, and were localized to the 
membrane-enriched fraction (Figure 12A). I detected no significant change in levels of 
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GluA1 or GluA2 in all dopamine-denervated animals or in the moderate and severe 
depletion groups, relative to control subjects. (Figure 12B). 
 
Altered mGluR 2/3 expression. The antibody to mGluR2/3 detected a clear band at 96 
kDa, as well as a higher molecular weight band of ~225 kDa. The majority of protein 
expression was seen in the membrane-enriched fraction (Fig 12A). Following dopamine 
depletion, PFC levels of the Group II metabotropic glutamate receptors were markedly 
increased in the membrane-enriched fraction compared to control animals (Fig 12B; p 
<0.05). Interestingly, when animals were separated into moderate and severe depletion 
groups, I observed that animals with moderate dopamine depletion had significantly 
greater expression of mGluR2/3 than controls (p<0.01), while animals with severe 






















Figure 12. Effect of dopamine depletion on glutamate-related proteins. A) Fraction 
localization of proteins examined by western blot. B) Moderate dopamine depletion 
leads to a significant increase in mGluR2/3 levels, while levels of other glutamate 
related-proteins remain consistent with controls following severe dopamine depletion. 
All other proteins were unaffected following both moderate and severe dopamine 
depletion. C) Representative blot showing increased mGluR2/3 following moderate 
dopamine depletion. 
---- 
















































xCT antibody characterization. I tried a number of different antibodies generated against 
xCT in an attempt to find one that was specific for xCT (see Table 8).  Tests with all of 
these antibodies resulted in multiple bands when probing the membrane fraction, 
including, in some cases, bands at the predicted mass for xCT (see Figure 13).  In order 
to help determine if any of these antibodies recognized xCT in addition to other proteins, 
I obtained tissue from xCT knockout mice, courtesy of Dr. Hideyo Sato (Yamagata 
University, Japan) (Sato et al., 2005). Unfortunately, studies with the knockout cortex 
failed to reveal that any of the 4 antibodies recognized xCT (Figure 13). I therefore did 
















Figure 13. Failure of xCT antibodies to detect differences between wildtype and xCT-
knockout animals. Antibodies from three sources are shown, in which no difference is 
observed between wildtype and knockout tissue, illustrating the ineffectiveness of the 









In Chapter 4, I demonstrated that dopamine depletion leads to increases in protein 
levels of the astrocytic glutamate transporter GLT-1. Interestingly, this increase is not 
accompanied by a parallel increase in the neuronal glutamate transporter EAAC1, 
suggesting that dopamine depletion may lead to an astrocyte-specific upregulation of 
glutamate uptake. The current chapter focuses on proteins involved in glutamate 
homeostasis that are localized to neurons, and have also, in a few cases, been 
described on astrocytes (AMPA and NMDA receptors and mGluR3).  The functional 
significance of the astocytically expressed proteins remains unclear. 
Proteins known to be critical to synaptic glutamate signaling, including the AMPA 
receptor and NMDA receptor subunits, showed no significant changes in response to 
dopamine depletion. We have not explored the possibility of functional changes in these 
proteins following dopamine depletion. Subunit composition of NMDA receptors can 
lead to significant variations in function and localization (Wyllie et al 2013). Similarly, 
phosphorylation states, which contribute to the functional effects of these proteins, were 
not examined. Thus, studies aimed at determining NMDA receptor function and 
composition may help us to better understand the effects of dopamine depletion on 
glutamatergic signaling through ionotropic glutamate receptors.  
 Unfortunately, none of the four putative xCT antibodies that I tested specifically 
recognized xCT, despite the fact that some have been used in previous studies 
(Knackstedt et al., 2009; Pampliega et al., 2011). However, in these earlier papers the 
full gel is not shown, only a narrow area of the gel surrounding the predicted mass of 
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xCT, and thus it is not possible to know if they used an antibody from a different animal 
or a different lot (bleed) that did recognize xCT. In the absence of specific xCT 
antibodies, future studies could evaluate radiolabeled cystine uptake to evaluate system 
xC-.  
I observed a significant increase in mGluR2/3 protein levels in the dopamine-
denervated PFC. Interestingly, while mGluR2 and 3 are both found on the presynaptic 
terminal, mGluR3 is also expressed on astrocytic membranes (Ohishi et al., 1993; 
Petralia et al., 1996). Presynaptic Group II mGluRs inhibit presynaptic release of 
glutamate, if the coupling mechanisms to astrocytic vesicule-like bodies that contain Glu 
are the same in astrocytes as in neurons there might be a corresponding decrease in 
Glu release. However, to the best of my knowledge this possibility has not been 
examined. Future studies, aimed at determining the relative contributions of mGluR2 
and mGluR3 to the group II mGluR immunoreactivity increases in the present study, 
may shed light on the different roles of astrocytic and neuronal mGluRs. The functional 
effects of mGluR3 activation in astrocytes have only recently started to be explored.  
Interestingly, several studies have suggested that mGluR3 and GLT-1 may 
interact, although the exact mechanism remains unclear (Aronica et al., 2003; Huang et 
al., 2004; Bellesi and Conti, 2010). Thus, one must consider the possibility that 
increases in GLT-1 (also observed only following moderate dopamine depletion) may 
lead to increases in mGluR2/3, or vice versa. Intriguingly, Aronica and colleagues 
showed that application of an mGluR2/3 agonist to cultured astrocytes leads to 
increased levels of GLT-1 and GLAST (2003). It will therefore be interesting to 
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determine whether the parallel increases in GLT-1 and mGluR2/3 seen in our own study 


























TRANSCRIPT EXPRESSION OF GLUTAMATE-RELATED PROTEINS FOLLOWING 
DOPAMINE DEPLETION OF THE PREFRONTAL CORTEX 
  
I found that dopamine depletion of the prefrontal cortex increases mGluR2/3 protein 
levels, as discussed in the previous chapter. However, I unable to determine if this 
increase reflected a change in mGluR2, which is restricted to neurons (Ohishi et al., 
1998), or mGluR3, which is expressed by astrocytes and neurons (Mudo et al., 2007; 
Harrison et al., 2008). Similarly, the lack of a specific antibody prevented me from 
assessing levels of xCT. In order to gain some insight into potential changes in xCT and 
group II mGluRs after PFC dopamine depletion, I examined the relative abundance of 





Methods used in this chapter are the same as those used in Chapter 6, with the 














Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
GluN1 ATGGAGGCCCGGGAACTGGAG CATTGCGGCTGCGCGGTACA 
GluA1 GGTGCGGTTGTGGGTGCCAAT  GGGCTCCGTGAGTTGTGACAAAG  
mGluR
2 CAGCAAGCGGGAACCGGAGC GAGGAGGAAACAGGGGCCAGGA 
mGluR
3 CTCACCGCTGCCGCTACCAC GGCTGAAAGAGCCCGTCACCG 
xCT CGCCGAGGAGCTGTTGCAGTC ATGGAGCCGAAGCAGGAGAGGG 
 








Extent of dopamine depletion. The dopamine concentration in the PFC of control 
animals averaged 0.49 ± 0.05 ng/mg protein. Prefrontal cortical dopamine 
concentrations in 6-hydroxydopamine-lesioned rats were reduced across all lesioned 
subjects by 74.3 % (t27= 7.36, p<0.001). Norepinephrine concentrations (control value of 
4.34 ± 0.25 ng/mg protein) were significantly reduced by 29.9% after dopamine 
denervation of the PFC (t27=2.92, p<0.01). Serotonin levels were unchanged. We also 
analyzed mRNA levels in animals separated into moderate and severe dopamine 
depletion groups, as described in Chapter 5.  The average decrease in PFC DA 
concentrations was 50.3% in the moderate group, and 89.6% depletion in the severe 
group (see Table 6 in Chapter 7). Norepinephrine levels were unchanged in the 
“moderate” dopamine depletion group, while levels of norepinephrine were reduced by 
28.9% in the “severe” dopamine depletion group (Table 6). Similar to the combined 
depletion groups, serotonin levels remained unchanged when animals were separated 
by dopamine depletion extent (Table 6). 
 
Effects of PFC dopamine depletion on mGluR2, mGluR3, and xCT mRNA levels.  When 
mRNA levels of mGluR3, mGluR2, GLUN1, GluR1, and xCT were evaluated by RT-
PCR, no change was observed in dopamine-depleted animals when compared to 
controls in any of the transcripts measured (Figure 14). Similarly, no change was 
observed in mGluR3, GLUN1, GluR1 or xCT transcripts when animals were separated 
by extent of dopamine depletion (Figure 14). However, in samples taken from animals 
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with “severe” dopamine depletion, a significant decrease in mGluR2 mRNA levels was 


















Figure 14.  RT-PCR following dopamine depletion of the PFC uncovers a significant 
decrease in mGluR2 mRNA levels. No change was observed in mRNA expression of 
the AMPA and NMDA receptor subunits GluA1 and GluN1 respectively. Similarly no 
change was observed in mGluR3 or xCT. A significant decrease was observed in 











mGluR2 and mGluR3 gene expression. We found that the mRNA encoding mGluR2 
was selectively increased in animals with severe dopamine depletion of the PFC. In 
contrast, we observed that mGluR2/3 protein levels were increased, but only in those 
animals with moderate, not severe, dopamine loss in the PFC.  
Unfortunately, this leaves us no closer to understanding how the increase we 
observed in mGluR2/3 protein levels in the group of animals sustaining moderate 
depletion of dopamine in the PFC occurs.  Indeed, the increase in mGluR2 mRNA that 
we uncovered in the severely dopamine depleted animals is difficult to put into any 
consistent framework with the other data we obtained.  We replicated the increase in 
mGluR2/3 protein levels twice, and thus have a total of three different experiments 
giving the same result.  However, we have not replicated in separate cohorts the mRNA 
data, which should be done.  Because the group II mGluRs function as release-
modulating autoreceptors, physiological studies in mGluR2 and mGluR3 knockout mice 
may offer the best chance of untangling how the contrasting changes we obtained in 
protein levels and mRNA relate.   
While the precise relationship between group II protein and mRNA levels remains 
obscure, it is of considerable interest that group II mGluR agonists applied to astrocytic 
cultures significantly increase GLT-1 levels (Aronica et al., 2003). This suggests that 
increases in mGluR2/3 immunoreactivity may drive the observed increase in GLT-1 in 
our in vivo experiments. Furthermore, these receptors appear to play an important role 
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in the astrocytic response to neuronal glutamate release, as activation of these 
receptors leads to increases in intracellular Ca2+ in astrocytes (Winder and Conn, 1996). 
 
xCT gene expression. Immunoblot studies of xCT protein levels produced inconclusive 
results, as discussed in Chapter 9. The data reported in this chapter suggest that xCT 
gene expression was unchanged following dopamine depletion of the PFC. 
Interestingly, like mGluR3, xCT has been linked to GLT-1. Knackstedt et al. showed that 
following cocaine administration, both xCT and GLT-1 were downregulated, and that 
administration of the beta-lactem antibiotic ceftriaxone, as well as N-acetylcysteine, 
could restore levels of both xCT and GLT-1 (2010). GLT-1 plays an important role in 
bringing glutamate into astrocytes; xCT exchanges intracellular glutamate for 
extracellular cystine, which is then used for production of the reducing agent glutathione 
(Sato et al., 2005; Shih et al., 2006). Therefore, the connection between these two 
proteins may be difficult to untangle if a challenge leads to the production of glutathione, 
as both are critical to glutathione production and disruption of one or the other of these 
proteins will effect the function of the other. Our data suggest that, rather than 
production of glutathione, restoration of glutamate homeostasis is the primary goal of 
the astrocyte following dopamine depletion, and therefore, xCT levels (and glutamate 
transport into the extracellular space) remain at normal levels, while increases in GLT-1 







FUNCTIONAL IMPLICATIONS, DISCUSSION, AND FUTURE DIRECTIONS 
 
Through the course of this dissertation I demonstrated that dopamine depletion 
increases protein levels of the astrocytic glutamate transporter GLT-1, without 
increasing GLT-1 mRNA levels. The increase in protein was not attributable to 
increased astrocyte number or activation. Furthermore, glutamate transport strongly 
correlated with the extent of dopamine depletion. No changes were observed in other 
glutamate transporters, nor a variety of proteins related to glutamate homeostasis, with 
the exception of mGluR2/3 protein, which showed the same relationship to dopamine 
denervation as GLT-1.  In this chapter, I will discuss the functional implications, 




Schizophrenia is a debilitating disease classically characterized by positive and 
negative symptoms. Positive symptoms include hallucinations, delusions, and thought 
disorder. Negative symptoms include flattened affect, a lack of motivation, and alogia. 
Cognitive symptoms of schizophrenia have gained significant attention in the last 30 
years, and include deficits in executive function, working memory, and attention. 
Improvements in cognitive symptoms correlate positively with patients’ overall outcome 
(Green, 2006; Tabarés-Seisdedos et al., 2008), which has led researchers to 
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investigate new therapeutics that aim to improve not only the positive and negative 
symptoms, but the cognitive deficits as well.  
 The prefrontal cortex is commonly associated with cognition. Morphological 
changes in the PFC, including decreases in volume as well as cellular changes, have 
been reported in patients with schizophrenia (Glantz and Lewis, 2000; Shenton et al., 
2010). The decreased volume is not accompanied by an overall loss of neurons, which 
has given rise to the reduced neuropil hypothesis of schizophrenia (Selemon and 
Goldman-Rakic, 1999).  This hypothesis suggests that the loss of dendritic or axonal 
processes contributes to PFC volume reduction. Consistent with this idea, loss of 
dendritic spines in the PFC is a consistently replicated pathological finding in 
schizophrenia (Garey et al., 1998; Glantz and Lewis, 2000; Black et al., 2004). 
However, the mechanism behind the loss of neuropil remains unclear. 
 Two primary hypotheses dominate current discussions of the pathophysiology of 
schizophrenia: the dopamine hypothesis and the glutamate hypothesis. Both PFC 
dopamine and glutamate have been shown to affect cognitive function and dendritic 
spine number in the prefrontal cortex (Sawaguchi and Goldman-Rakic, 1991; Krystal et 
al., 1994; Arnsten and Li, 2005; Carli et al., 2011). Current treatment options 
predominantly target subcortical hyperdopaminergia, which is thought to give rise to 
positive symptoms. Unfortunately, cognitive deficits remain one of the most difficult 
aspects of schizophrenia to treat. Thus, novel therapeutic strategies continue to be 
explored, including those that target aspects of glutamate signaling (de Bartolomeis et 
al., 2012; Kantrowitz and Javitt, 2012; Takahashi and Sakurai, 2013). Among the novel 
therapeutics aimed at reducing cognitive dysfunction, are various players in the 
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glutamate pathway, including mGluRs and allosteric modulatory sites on the NMDA 
receptor, including D-cycloserine and the the glycine transporter (which provides an 
essential NMDA co-agonist).  
 Yet the basic science question remains: do changes in dopamine lead to 
changes in glutamate, or vice versa? Understanding the interactions between dopamine 
and glutamate appears to be critical for understanding the role that the PFC plays in 
cognition. Therefore, schizophrenia is one field (of many) in which a detailed 
understanding of the interactions between these transmitters may lead to significant 
advances in therapeutics, particularly in the treatment of cognitive deficits seen in the 
disorder. 
 
Dopamine-Glutamate Interactions. As studies continue to explore the roles of both 
dopaminergic and glutamatergic signaling dysfunction in schizophrenia, it is becoming 
clear that the disease is not likely to be explained fully by one or the other, but rather by 
an understanding of the interactions between dopamine and glutamate. Thus, studies 
such as those described in this thesis, as well as others, which describe interactions 
and effects of dopamine on glutamate, and vice versa, are of particular importance. 
Moghaddam and colleagues used subanesthetic doses of the NMDA receptor 
antagonist ketamine, and measured dopamine and glutamate levels in the PFC and 
striatum using microdialysis (1997). These studies found that ketamine increases 
extracellular glutamate and dopamine levels in the PFC. Researchers have also 
investigated the effects of dopamine and pharmacological manipulation of dopamine 
receptors on glutamate receptor activation (Tseng and O'Donnell, 2004; Sokoloff et al., 
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2013; Yuen et al., 2013). In a study using slice electrophysiology, bath application of 
dopamine to the PFC resulted in a dose dependent increase in EPSC amplitude 
recorded in Layer II/III pyramidal cells, suggesting alterations in the postsynaptic 
response (Gonzalez-Islas and Hablitz, 2003).  In similar experiments with adult animals, 
agonists specific to D1 (SKF38393) or D2 (quinpirole) have differential effects, as 
SKF38393 elicits an increase in pyramidal cell excitability, while quinpirole induces a 
dose-dependent decrease in excitability (Tseng and O’Donnell, 2004). These data 
suggest that targeting dopamine receptors as a whole may be too broad a tool, and that 
subtype specific drugs may allow more specific treatments, if basic research is able to 
tease apart the contributions of these receptors to various disease states. Furthermore, 
Paille and colleagues demonstrated that dopamine depletion of the striatum produces 
differential effects on NMDA receptor subunit levels. Partial dopamine depletion (~75%) 
leads to increases in GluN2A, while a full depletion (>95%) has no effect on GluN2A, 
but leads to significantly lower levels of GluN2B (Paille et al., 2010). These data suggest 
that dopamine-glutamate interactions are quite complex, being dependent on 
concentrations of the transmitters involved, as well as the receptors expressed. 
Dopamine can impact presynaptic release of glutamate, as well as the postsynaptic 
response to released glutamate (Wang, 2001, Gonzalez-Islas et al., 2003). Similarly, 
glutamate can have a significant impact on dopamine release (Usun et al., 2013). While 
the interactions between dopamine and glutamate continue to be explored and defined, 
it is becoming increasingly clear that manipulation of the dopamine system is likely to 
have implications for the glutamate system, and vice versa. Thus far, investigation of 
dopamine-glutamate interactions has focused primarily on neurons. Over the past 
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decade it has become clear that glia, and particularly astrocytes, can no longer be 
regarded as passive support cells in the brain.  
Previous work examining the effects of dopamine on glutamate release has used 
pharmacological manipulation (Daly et al., 1997 Yamamoto and Cooperman, 1994), but 
there has been no work using chronic dopamine depletion as appears to occur in 
schizophrenia. Likewise, little work has been done investigating the effects of dopamine 
depletion on astrocytic glutamate-related proteins in any brain region, and no 
investigations have been done in the PFC. I therefore investigated the effect of 
dopamine depletion on both neuronal and astrocytic glutamate-related proteins in the 
PFC in an effort to fill this knowledge gap.  
In the previous chapters, I have demonstrated that dopamine depletion of the 
prefrontal cortex leads to increases in GLT-1 and mGluR2/3, two proteins that are 
expressed (although not exclusively) by astrocytes. When samples were separated by 
the extent of dopamine depletion, the observed effect was limited to those animals 
suffering a “moderate” depletion as opposed to a “severe” depletion. The observed 
changes were specific to the membrane-bound fraction, and were not paralleled by 
changes in gene expression. Furthermore, increases were not attributable to 
astrocytosis, leading us to suggest that disrupted post-translational modification may be 
the cause of GLT-1 increases, specifically.  Interestingly, as seen in Chapter 8, 
functional assays revealed that the extent of dopamine depletion correlates positively 
with the rate of glutamate uptake. All of these data point to an astrocytic response to 




Limitations and Future Studies 
 
As with all scientific studies, those studies described in this thesis have limitations, 
some of which have been mentioned within the previous chapters. Several of these 
limitations, and experiments that could address them, will be discussed in more detail in 
the following section. 
 
What happens to extracellular glutamate levels? I have hypothesized that dopamine 
depletion of the PFC leads to increases in extracellular glutamate, and thus leads to 
changes in proteins such as GLT-1 and mGluR2/3. At this point studies demonstrating 
this increase in glutamate levels have not been performed. However, preliminary 
studies aimed at addressing this hypothesis have been done using electrophysiological 
assessment of spontaneous EPSC number. Contrary to our expectations, no difference 
was seen in the frequency of spontaneous EPSCs in lesioned animals compared to 
controls. However, when these experiments were performed, we had not yet 
established differences between “moderate” and “severe” dopamine depletion. 
Therefore, the extent of dopamine depletion was not addressed in these experiments. 
Future studies aimed at determining the effect of dopamine depletion of the PFC on 
extracellular levels of glutamate would likely prove to be very useful, not only for 
improving the interpretation of our own data, but also for numerous other labs studying 
the interactions of these transmitters. 
While electrophysiology can produce valuable insight into the release of 
glutamate, it is difficult to determine if basal extracellular levels of glutamate are 
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increased using these techniques. A more direct measure of glutamate levels following 
dopamine depletion could be achieved using microdialysis. However, traditional 
microdialysis requires establishing a baseline concentration, before administration of a 
challenge, after which the response to this challenge can be determined. This technique 
has been utilized in the presence of dopamine antagonists. Traditional microdialysis 
experiments are not capable of measuring true concentrations of glutamate for 
comparison between control animals and animals receiving a VTA lesion. Rather 
traditional microdialysis requires the addition of a challenge, often K+ stimulation. In 
order to determine the extracellular glutamate levels following dopamine depletion, a 
technique known as no-net-flux or stable-isotope-labelling should be used (Olson and 
Justice, 1993; Hershey and Kennedy, 2013). These methods allow the experimenter to 
determine a true concentration of glutamate or other molecules without the use of a 
challenge or stimulation. Use of these techniques, while difficult, could prove to be very 
helpful in determining the effect of chronic dopamine depletion on extracellular 
glutamate concentrations. Furthermore, these experiments could help to elucidate the 
source of the differential response to varied dopamine depletions. It could be that 
moderate and severe dopamine depletions have differential effects on extracellular 
glutamate levels, leading to increases or activation of different sets of proteins. 
However, while these experiments could help to explain why there are different 
responses to varied extents of dopamine depletion, it would do little to determine what 




Why is there an increase in GLT-1 and mGluR2/3 following moderate dopamine 
depletion and no increase following severe dopamine depletion? One question that has 
come out of the work presented in this thesis is: why is there an increase in GLT-1 and 
mGluR2/3 levels following moderate dopamine depletion, but not after severe dopamine 
depletion? This question certainly deserves significant attention. I have hypothesized 
that differential mechanisms likely exist following moderate depletion when compared to 
severe dopamine depletion. Thus an astrocytic response, as seen through increases in 
GLT-1, occurs following moderate depletion, while another, as yet undefined, 
mechanism may occur after severe dopamine depletion.  A number of proteins that may 
be potential players in a secondary neuronal mechanism, including NMDA receptor 
subunits and AMPA receptor subunits, have been examined without an observed 
change (see Chapter 9). However, the phosphorylation states of these proteins were 
not examined. Differences in phosphorylation can lead to significant functional changes 
in a protein (Moon et al., 1994; Rostas et al., 1996; Giese et al., 1998; Strack, 1998). 
Therefore, examining some of these proteins more thoroughly, with regards to post-
translational modifications might provide insight into a potential response to severe 
dopamine depletion. 
Another possible explanation for increased GLT-1 and mGluR2/3 following 
moderate dopamine depletion with no change following severe dopamine depletion, 
which was raised in Chapter 5, is that following severe dopamine depletion there is a 
loss of dendritic spines that may not be observed after moderate dopamine depletion. 
Previous work by myself and others in our lab have laid the groundwork for studies 
exploring the effects of varied extents of dopamine depletion on dendritic spine density 
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of PFC pyramidal cells. Previously published work has demonstrated that dopamine 
depletion of the PFC results in a loss of dendritic spines on Layer V pyramidal cells 
(Wang and Deutch, 2008). Since the publication of this data, our lab has switched from 
Golgi staining to intracellular fills using the dye Lucifer Yellow, which allows for the 
selection of non-overlapping neurons for processing, and also allows us to take 
intermittent sections for immunohistochemistry. The sections can then be stained with a 
TH antibody in an effort to determine the extent of dopamine depletion in individual 
animals. In order to verify that this method produces a good representation of dopamine 
depletion, we correlated dopamine concentration, as determined by HPLC analysis, to 
the total length of TH positive axons in the PFC (Figure 15). Using intracellular fills 
along with TH axon length, experiments can now be performed to evaluate the effects of 
dopamine depletion on the number of dendritic spines. This could help to determine 
whether dendritic spine loss might be a mechanism that is restricted to those animals 
with severe dopamine depletion, while GLT-1 and mGluR2/3 increases only occur in 
animals with moderate dopamine depletion. 
 It may be that both of these experiments will fail to yield significant differences 
between moderate and severe dopamine depletion, and that the observed difference in 
protein expression will need to be explained through another, currently undefined, 
mechanism. However, understanding why there is a differential response in moderate, 
compared to severe dopamine depletions remains a critical question that should be 
















Figure 15. Comparison of TH axon density and HPLC dopamine levels in the PFC 
following dopamine depletion. Two methods were used to determine the extent of 
dopamine depletion of the same animals, HPLC analysis, and TH axon density. A) TH 
axon density strongly correlated with dopamine levels determined by HPLC analysis. B) 
Representative images of TH tracings for a control (top) and a lesioned animal (bottom). 
wm=white matter; ps= pial surface  
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Can we be certain that GLT-1 increases are astrocytic? Some controversy exists over 
the localization of GLT-1. The majority of researchers appear to be in agreement that 
GLT-1 protein is exclusively, or nearly exclusively, expressed by astrocytes in the adult 
rodent brain under normal conditions (Danbolt, 2001; Kanai et al., 2013). However, 
research has also demonstrated that there are circumstances in which GLT-1 can be 
expressed by neurons. When hippocampal neurons are grown in culture, for example, 
these cells have been shown to express the glutamate transporter GLT-1 (Mennerick et 
al., 1998). Furthermore, ischemic conditions in vivo have been shown to lead to 
neuronal expression of GLT-1 protein (Martin et al., 1997). Interestingly, GLT-1 mRNA 
has been observed in neurons in vivo, despite a lack of protein expression (Schmitt et 
al., 1997; Torp et al., 1997). These data suggest that under certain conditions, neuronal 
GLT-1 expression may be induced. Our results demonstrate that there is no increase in 
levels of GLT-1 mRNA following dopamine depletion, yet there is a significant increase 
in protein expression. We have suggested that this is due to an accumulation of GLT-1 
in astrocytic membranes, since the majority of researchers believe that GLT-1 is 
overwhelmingly expressed in astrocytes. Future experiments using electron microscopy 
should be performed to determine the localization of GLT-1 protein expression following 
dopamine depletion, resolving this issue more concretely. However, the increases in 
GLT-1 that we have observed, regardless of neuronal or astrocytic localization, 
represent a substantial response in a protein involved in glutamate signaling following 
dopamine depletion. This further solidifies the need for extensive research into the 




Are glutamate uptake results solely attributable to GLT-1? In Chapter 8, the effect of 
dopamine depletion on glutamate uptake was determined. In this experiment, specific 
glutamate uptake was determined by subtracting non-specific uptake as determined by 
running samples through the same uptake protocol while keeping samples on ice, 
effectively preventing all transport. We have assumed that glutamate uptake in the 
cortex occurs almost entirely through the GLT-1 transporter, as has been reported by 
multiple investigators (Rothstein et al., 1996, Tanaka et al., 1997). However, following 
inhibition of GLT-1, upregulation of EAAC1 transport has been reported (Salvatore et 
al., 2012), suggesting that under certain conditions the burden of transport can shift 
away from GLT-1.  
 Chapter 8 also demonstrated that glutamate uptake positively correlated with the 
extent of dopamine depletion, contrary to the negative correlation observed between 
dopamine depletion and GLT-1 protein expression. This suggests that GLT-1 function 
differs between varied extents of dopamine depletion, or that glutamate uptake shifts 
from being mediated primarily by GLT-1 to include a greater contribution by other 
transporters (i.e. GLAST or EAAC1).  
 Experiments aimed at determining glutamate uptake specific to the different 
transporters following dopamine depletion may prove useful in determining whether 
there is a shift from transport primarily through GLT-1 to one of the other transporters. 
Through the use of inhibitors specific to GLT-1 (dihydrokainate; Bunch et al., 2009), 
GLAST (UCPH-1;Abrahamsen et al., 2013) and EAAC1 (HIP-B;Callender et al., 2012), 
it could be determined whether major changes in transporter function occur as a result 
of varied dopamine depletions. However, despite being used as specific inhibitors, one 
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would need to be careful in interpreting results from these studies, closely examining 
the specificity of the inhibition, not just between glutamate transporters, but other targets 
as well.  
 
Does dopamine depletion directly affect astrocytes, or do effects of dopamine depletion 
on neurons lead to the astrocytic response? The experiments contained in this 
document do not address the question of which cell type is directly affected by 
dopamine depletion. For example, loss of dopamine signaling at astrocytic dopamine 
receptors may lead to intracellular signaling which ultimately leads to increased 
expression of GLT-1 and mGluR2/3. In contrast, a decrease in dopamine signaling at 
neuronal dopamine receptors may lead to increased glutamate release and a 
subsequent increase in levels of glutamate-related proteins including GLT-1 and 
mGluR2/3.  
Astrocytes and neurons each express dopamine receptors, making this question 
difficult to address through in vivo experiments. In vitro cultures using astrocytes and 
neurons may provide an experimental model that allows for the separation of neuronal 
and astrocytic effects, although complications also exist with this technique. Initially, a 
simple astrocyte culture system using dopamine receptor antagonists (towards both D1 
and D2 receptors) followed by western blot analysis of GLT-1 and mGluR2/3 levels 
could give some insight into astrocytic responses to dopamine depletion. Unfortunately, 
astrocytes and neurons have been shown to have very different protein expression 
patterns in vitro when compared to in vivo (Lehmann and Harris, 1995; Mennerick et al., 
1998). Thus, changes observed in cell-type specific cultures could be significantly 
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different from in vivo responses that are presumably more closely resemble the human 
in vivo condition.  
 Co-culture of astrocytes and neurons is frequently used to better represent the 
environment present in vivo, and a recent co-culture system allows for the culturing of 
astrocytes and neurons from different genetic backgrounds (Jones et al., 2012). Using 
genetically modified animals lacking the dopamine receptors, cultures could include 
unmodified neurons and astrocytes without dopamine receptors. Using these cultures 
one could determine whether a lack of dopamine signaling at astrocytic dopamine 
receptors leads to GLT-1 and mGluR2/3 protein increases. Similarly, neurons lacking 
dopamine receptors could be cultured with unmodified astrocytes to determine whether 
a lack of dopamine signaling on neurons leads to increased GLT-1 or mGluR2/3 protein. 
However, modeling chronic dopamine depletion, as we have utilized in our in vivo 
models, would remain difficult. 
 Relevant techniques available to tease apart the effects of dopamine depletion 
on astrocytes and neurons remain limited.  To effectively mimic our experimental 
paradigm in vivo, a co-culture including astrocytes and neurons, in which one cell–type 
could be treated, but not the other, would be ideal. To the best of my knowledge this 
technique does not yet exist. However, through the use of optogenetics, one might be 
able to transfect astrocytes or neurons with light-inhibited dopamine receptors. By 
culturing these, along with wild-type neurons or astrocytes, respectively, one might be 
able to tease apart the different contributions of astrocyte and neuron dopamine 
depletion to GLT-1 and mGluR2/3 changes. Unfortunately, the methods available to us 
in pursuing the effects of dopamine depletion on a complete astrocyte-neuron system, 
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appear to be inadequate. Advances in culture (or in vivo) systems may make these 






This work has demonstrated that dopamine depletion of the prefrontal cortex, similar to 
that observed in schizophrenia, can lead to alterations in the expression of glutamate-
related proteins. In particular, we show that dopamine depletion has a significant effect 
on the astrocytic glutamate transporter, GLT-1. The study of astrocytes continues to 
expand, and our work suggests that astrocytes may be an integral part of dopamine-
glutamate interactions. Future studies, building off the work in this thesis, may 
demonstrate that these once overlooked cells play a critical role in linking the dopamine 
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